84 results on '"P, Genne"'
Search Results
2. Coronal Heating as Determined by the Solar Flare Frequency Distribution Obtained by Aggregating Case Studies
- Author
-
Mason, James Paul, Werth, Alexandra, West, Colin G., Youngblood, Allison A., Woodraska, Donald L., Peck, Courtney, Lacjak, Kevin, Frick, Florian G., Gabir, Moutamen, Alsinan, Reema A., Jacobsen, Thomas, Alrubaie, Mohammad, Chizmar, Kayla M., Lau, Benjamin P., Dominguez, Lizbeth Montoya, Price, David, Butler, Dylan R., Biron, Connor J., Feoktistov, Nikita, Dewey, Kai, Loomis, N. E., Bodzianowski, Michal, Kuybus, Connor, Dietrick, Henry, Wolfe, Aubrey M., Guerrero, Matt, Vinson, Jessica, Starbuck, Peter, Litton, Shelby D, Beck, M. G., Fisch, Jean-Paul, West, Ayana, Muniz, Alexis A., Chavez, Luis, Upthegrove, Zachary T., Runyon, Brenton M., Salazar, J., Kritzberg, Jake E., Murrel, Tyler, Ho, Ella, LaFemina, Quintin Y., Elbashir, Sara I., Chang, Ethan C., Hudson, Zachary A., Nussbaum, Rosemary O., Kennedy, Kellen, Kim, Kevin, Arango, Camila Villamil, Albakr, Mohammed A., Rotter, Michael, Garscadden, A. J., Salcido-Alcontar JR, Antonio, Pearl, Harrison M., Stepaniak, Tyler, Marquez, Josie A., Marsh, Lauren, Andringa, Jesse C, Osogwin, Austin, Shields, Amanda M., Brookins, Sarah, Hach, Grace K., Clausi, Alexis R., Millican, Emily B., Jaimes, Alan A, Graham, Alaina S., Burritt, John J., Perez, J. S., Ramirez, Nathaniel, Suri, Rohan, Myer, Michael S., Kresek, Zoe M., Goldsberry, C. A., Payne, Genevieve K., Jourabchi, Tara, Hu, J., Lucca, Jeffrey, Feng, Zitian, Gilpatrick, Connor B., Khan, Ibraheem A., Warble, Keenan, Sweeney, Joshua D., Dorricott, Philip, Meyer, Ethan, Kothamdi, Yash S., Sohail, Arman S., Grell, Kristyn, Floyd, Aidan, Bard, Titus, Mathieson, Randi M., Reed, Joseph, Cisneros, Alexis, Payne, Matthew P., Jarriel, J. R., Mora, Jacqueline Rodriguez, Sundell, M. E., Patel, Kajal, Alesmail, Mohammad, Alnasrallah, Yousef A, Abdullah, Jumana T., Molina-Saenz, Luis, Tayman, K. E., Brown, Gabriel T., Kerr-Layton, Liana, Berriman-Rozen, Zachary D., Hiatt, Quinn, Kalra, Etash, Ong, Jason, Vadayar, Shreenija, Shannahan, Callie D., Benke, Evan, zhang, Jinhua, Geisman, Jane, Martyr, Cara, Ameijenda, Federico, Akruwala, Ushmi H., Nehring, Molly, Kissner, Natalie, Rule, Ian C., Learned, Tyler, Smith, Alexandra N., Mazzotta, Liam, Rounsefell, Tyndall, Eyeson, Elizabeth A., Shelby, Arlee K., Moll, Tyler S, Menke, Riley, Shahba, Hannan, House Jr., Tony A., Clark, David B., Burns, Annemarie C., de La Beaujardiere, Tristan, Trautwein, Emily D., Plantz, Will, Reeves, Justin, Faber, Ian, Buxton, B. W., Highhouse, Nigel, Landrey, Kalin, Hansen, Connor M, Chen, Kevin, Hales, Ryder Buchanan, Borgerding, Luke R., Guo, Mutian, Crow, Christian J., Whittall, Lloyd C., Simmons, Conor, Folarin, Adeduni, Parkinson, Evan J., Rahn, Anna L., Blevins, Olivia, Morelock, Annalise M., Kelly, Nicholas, Parker, Nathan L., Smith, Kelly, Plzak, Audrey E., Saeb, David, Hares, Cameron T., Parker, Sasha R., McCoy, Andrew, Pham, Alexander V., Lauzon, Megan, Kennedy, Cayla J., Reyna, Andrea B., Acosta, Daniela M. Meza, Cool, Destiny J., Steinbarth, Sheen L., Mendoza-Anselmi, Patricia, Plutt, Kaitlyn E., Kipp, Isabel M, Rakhmonova, M., Brown, Cameron L., Van Anne, Gabreece, Moss, Alexander P., Golden, Olivia, Kirkpatrick, Hunter B., Colleran, Jake R., Sullivan, Brandon J, Tran, Kevin, Carpender, Michael Andrew, Mundy, Aria T., Koenig, Greta, Oudakker, Jessica, Engelhardt, Rasce, Ales, Nolan, Wexler, Ethan Benjamin, Beato, Quinn I, Chen, Lily, Cochran, Brooke, Hill, Paula, Hamilton, Sean R., Hashiro, Kyle, Khan, Usman, Martinez, Alexa M., Brockman, Jennifer L., Mallory, Macguire, Reed, Charlie, Terrile, Richard, Singh, Savi, Watson, James Adam, Creany, Joshua B., Price, Nicholas K., Miften, Aya M., Tran, Bryn, Kamenetskiy, Margaret, Martinez, Jose R., Opp, Elena N., Huang, Jianyang, Fails, Avery M., Belei, Brennan J., Slocum, Ryan, Astalos, Justin, East, Andrew, Nguyen, Lena P., Pherigo, Callie C, East, Andrew N., Li, David Y., Nelson, Maya LI, Taylor, Nicole, Odbayar, Anand, Rives, Anna Linnea, Mathur, Kabir P., Billingsley, Jacob, Polikoff, Hyden, Driscoll, Michael, Wilson, Orion K., Lahmers, Kyle, Toon, Nathaniel J., Lippincott, Sam, Musgrave, Andrew J., Gregory, Alannah H., Pitsuean-Meier, Sedique, Jesse, Trevor, Smith, Corey, Miles, Ethan J., Kainz, Sabrina J. H. T., Ji, Soo Yeun, Nguyen, Lena, Aryan, Maryam, Dinser, Alexis M., Shortman, Jadon, Bastias, Catalina S, Umbricht, Thomas D, Cage, Breonna, Randolph, Parker, Pollard, Matthew, Simone, Dylan M., Aramians, Andrew, Brecl, Ariana E., Robert, Amanda M., Zenner, Thomas, Saldi, Maxwell, Morales, Gavin, Mendez, Citlali, Syed, Konner, Vogel, Connor Maklain, Cone, Rebecca A., Berhanu, Naomi, Carpenter, Emily, Leoni, Cecilia, Bryan, Samuel, Ramachandra, Nidhi, Shaw, Timothy, Lee, E. C., Monyek, Eli, Wegner, Aidan B., Sharma, Shajesh, Lister, Barrett, White, Jamison R., Willard, John S., Sulaiman, S. A, Blandon, Guillermo, Narayan, Anoothi, Ruger, Ryan, Kelley, Morgan A., Moreno, Angel J., Balcer, Leo M, Ward-Chene, N. R. D., Shelby, Emma, Reagan, Brian D., Marsh, Toni, Sarkar, Sucheta, Kelley, Michael P., Fell, Kevin, Balaji, Sahana, Hildebrand, Annalise K., Shoha, Dominick, Nandu, Kshmya, Tucker, Julia, Cancio, Alejandro R., Wang, Jiawei, Rapaport, Sarah Grace, Maravi, Aimee S., Mayer, Victoria A., Miller, Andrew, Bence, Caden, Koke, Emily, Fauntleroy, John T, Doermer, Timothy, Al-Ghazwi, Adel, Morgan, Remy, Alahmed, Mohammed S., Mathavan, Adam Izz Khan Mohd Reduan, Silvester, H. K., Weiner, Amanda M., Liu, Nianzi, Iovan, Taro, Jensen, Alexander V., AlHarbi, Yazeed A., Jiang, Yufan, Zhang, Jiaqi, Jones, Olivia M., Huang, Chenqi, Reh, Eileen N., Alhamli, Dania, Pettine, Joshua, Zhou, Chongrui, Kriegman, Dylan, Yang, Jianing, Ash, Kevin, Savage, Carl, Kaiser, Emily, Augenstein, Dakota N., Padilla, Jacqueline, Stark, Ethan K., Hansen, Joshua A., Kokes, Thomas, Huynh, Leslie, Sanchez-Sanchez, Gustavo, Jeseritz, Luke A., Carillion, Emma L., Vepa, Aditya V., Khanal, Sapriya, Behr, Braden, Martin, Logan S., McMullan, Jesse J., Zhao, Tianwei, Williams, Abigail K., Alqabani, Emeen, Prinster, Gale H., Horne, Linda, Ruggles-Delgado, Kendall, Otto, Grant, Gomez, Angel R., Nguyen, Leonardo, Brumley, Preston J., Venegas, Nancy Ortiz, Varela, Ilian, Brownlow, Jordi, Cruz, Avril, Leiker, Linzhi, Batra, Jasleen, Hutabarat, Abigail P., Nunes-Valdes, Dario, Jameson, Connor, Naqi, Abdulaziz, Adams, Dante Q., Biediger, Blaine B., Borelli, William T, Cisne, Nicholas A., Collins, Nathaniel A., Curnow, Tyler L., Gopalakrishnan, Sean, Griffin, Nicholas F., Herrera, Emanuel, McGarvey, Meaghan V., Mellett, Sarah, Overchuk, Igor, Shaver, Nathan, Stratmeyer, Cooper N., Vess, Marcus T., Juels, Parker, Alyami, Saleh A., Gale, Skylar, Wallace, Steven P., Hunter, Samuel C, Lonergan, Mia C., Stewart, Trey, Maksimuk, Tiffany E., Lam, Antonia, Tressler, Judah, Napoletano, Elena R., Miller, Joshua B., Roy, Marc G., Chanders, Jasey, Fischer, Emmalee, Croteau, A. J., Kuiper, Nicolas A., Hoffman, Alex, DeBarros, Elyse, Curry, Riley T., Brzostowicz, A., Courtney, Jonas, Zhao, Tiannie, Szabo, Emi, Ghaith, Bandar Abu, Slyne, Colin, Beck, Lily, Quinonez, Oliver, Collins, Sarah, Madonna, Claire A., Morency, Cora, Palizzi, Mallory, Herwig, Tim, Beauprez, Jacob N., Ghiassi, Dorsa, Doran, Caroline R., Yang, Zhanchao, Padgette, Hannah M., Dicken, Cyrus A., Austin, Bryce W., Phalen, Ethan J., Xiao, Catherine, Palos, Adler, Gerhardstein, Phillip, Altenbern, Ava L., Orbidan, Dan, Dorr, Jackson A., Rivas, Guillermo A., Ewing, Calvin A, Giebner, B. C., McEntee, Kelleen, Kite, Emily R., Crocker, K. A., Haley, Mark S., Lezak, Adrienne R., McQuaid, Ella, Jeong, Jacob, Albaum, Jonathan, Hrudka, E. M., Mulcahy, Owen T., Tanguma, Nolan C., Oishi-Holder, Sean, White, Zachary, Coe, Ryan W., Boyer, Christine, Chapman, Mitchell G., Fortino, Elise, Salgado, Jose A., Hellweg, Tim, Martinez, Hazelia K., Mitchell, Alexander J., Schubert, Stephanie H., Schumacher, Grace K, Tesdahl, Corey D, Uphoff, C. H., Vassilyev, Alexandr, Witkoff, Briahn, Wolle, Jackson R., Dice, Kenzie A., Behrer, Timothy A., Bowen, Troy, Campbell, Andrew J, Clarkson, Peter C, Duong, Tien Q., Hawat, Elijah, Lopez, Christian, Olson, Nathaniel P., Osborn, Matthew, Peou, Munisettha E., Vaver, Nicholas J., Husted, Troy, Kallemeyn, Nicolas Ian, Spangler, Ava A, Mccurry, Kyle, Schultze, Courtney, Troisi, Thomas, Thomas, Daniel, Ort, Althea E., Singh, Maya A., Soon, Caitlin, Patton, Catherine, Billman, Jayce A., Jarvis, Sam, Hitt, Travis, Masri, Mirna, Albalushi, Yusef J., Schofer, Matthew J, Linnane, Katherine B., Knott, Philip Whiting, Valencia, Whitney, Arias-Robles, Brian A., Ryder, Diana, Simone, Anna, Abrams, Jonathan M., Belknap, Annelene L., Rouse, Charlotte, Reynolds, Alexander, Petric, Romeo S. L., Gomez, Angel A., Meiselman-Ashen, Jonah B., Carey, Luke, Dias, John S., Fischer-White, Jules, Forbes, Aidan E., Galarraga, Gabriela, Kennedy, Forrest, Lawlor, Rian, Murphy, Maxwell J., Norris, Cooper, Quarderer, Josh, Waller, Caroline, Weber, Robert J., Gunderson, Nicole, Boyne, Tom, Gregory, Joshua A., Propper, Henry Austin, von Peccoz, Charles B. Beck, Branch, Donovan, Clarke, Evelyn, Cutler, Libby, Dabberdt, Frederick M., Das, Swagatam, Figueirinhas, John Alfred D., Fougere, Benjamin L., Roy, Zoe A., Zhao, Noah Y., Cox, Corben L., Barnhart, Logan D. W., Craig, Wilmsen B., Moll, Hayden, Pohle, Kyle, Mueller, Alexander, Smith, Elena K., Spicer, Benjamin C., Aycock, Matthew C., Bat-Ulzii, Batchimeg, Murphy, Madalyn C., Altokhais, Abdullah, Thornally, Noah R., Kleinhaus, Olivia R., Sarfaraz, Darian, Barnes, Grant M., Beard, Sara, Banda, David J, Davis, Emma A. B., Huebsch, Tyler J., Wagoner, Michaela, Griego, Justus, Hale, Jack J. Mc, Porter, Trevor J., Abrashoff, Riley, Phan, Denise M., Smith, Samantha M., Srivastava, Ashish, Schlenker, Jared A. W., Madsen, Kasey O., Hirschmann, Anna E., Rankin, Frederick C, Akbar, Zainab A., Blouin, Ethan, Coleman-Plante, Aislinn, Hintsa, Evan, Lookhoff, Emily, Amer, Hamzi, Deng, Tianyue, Dvorak, Peter, Minimo, Josh, Plummer, William C., Ton, Kelly, Solt, Lincoln, AlAbbas, Batool H., AlAwadhi, Areej A., Cooper, Nicholas M., Corbitt, Jessica S, Dunlap, Christian, Johnson, Owen, Malone, Ryan A., Tellez, Yesica, Wallace, Logan, Ta, Michael-Tan D., Wheeler, Nicola H., Ramirez, Ariana C., Huang, Shancheng, Mehidic, Amar, Christiansen, Katherine E, Desai, Om, Domke, Emerson N., Howell, Noah H., Allsbrook, Martin, Alnaji, Teeb, England, Colin, Siles, Nathan, Burton, Nicholas David, Cruse, Zoe, Gilmartin, Dalton, Kim, Brian T., Hattendorf, Elsie, Buhamad, Maryam, Gayou, Lily, Seglem, Kasper, Alkhezzi, Tameem, Hicks, Imari R., Fife, Ryann, Pelster, Lily M., Fix, Alexander, Sur, Sohan N., Truong, Joshua K., Kubiak, Bartlomiej, Bondar, Matthew, Shi, Kyle Z., Johnston, Julia, Acevedo, Andres B., Lee, Junwon, Solorio, William J., Johnston, Braedon Y., McCormick, Tyler, Olguin, Nicholas, Pastor, Paige J., Wilson, Evan M., Trunko, Benjamin L., Sjoroos, Chris, Adams, Kalvyn N, Bell, Aislyn, Brumage-Heller, Grant, Canales, Braden P., Chiles, Bradyn, Driscoll, Kailer H., Hill, Hallie, Isert, Samuel A., Ketterer, Marilyn, Kim, Matthew M., Mewhirter, William J., Phillips, Lance, Phommatha, Krista, Quinn, Megan S., Reddy, Brooklyn J., Rippel, Matthew, Russell, Bowman, Williams, Sajan, Pixley, Andrew M., Gapin, Keala C., Peterson, B., Ruprecht, Collin, Hardie, Isabelle, Li, Isaac, Erickson, Abbey, Gersabeck, Clint, Gopalani, Mariam, Allanqawi, Nasser, Burton, Taylor, Cahn, Jackson R., Conti, Reese, White, Oliver S., Rojec, Stewart, Hogen, Blake A., Swartz, Jason R., Dick, R., Battist, Lexi, Dunn, Gabrielle M., Gasser, Rachel, Logan, Timothy W., Sinkovic, Madeline, Schaller, Marcus T., Heintz, Danielle A., Enrich, Andrew, Sanchez, Ethan S., Perez, Freddy, Flores, Fernando, Kapla, Shaun D., Shockley, Michael C., Phillips, Justin, Rumley, Madigan, Daboub, Johnston, Karsh, Brennan J., Linders, Bridget, Chen, Sam, Do, Helen C., Avula, Abhinav, French, James M., Bertuccio, Chrisanna, Hand, Tyler, Lee, Adrianna J., Neeland, Brenna K, Salazar, Violeta, Andrew, Carter, Barmore, Abby, Beatty, Thomas, Alonzi, Nicholas, Brown, Ryan, Chandler, Olivia M., Collier, Curran, Current, Hayden, Delasantos, Megan E., Bonilla, Alberto Espinosa de los Monteros, Fowler, Alexandra A., Geneser, Julianne R., Gentry, Eleanor, Gustavsson, E. R., Hansson, Jonathan, Hao, Tony Yunfei, Herrington, Robert N., Kelly, James, Kelly, Teagan, Kennedy, Abigail, Marquez, Mathew J., Meillon, Stella, Palmgren, Madeleine L., Pesce, Anneliese, Ranjan, Anurag, Robertson, Samuel M., Smith, Percy, Smith, Trevor J, Soby, Daniel A., Stratton, Grant L., Thielmann, Quinn N., Toups, Malena C., Veta, Jenna S., Young, Trenton J., Maly, Blake, Manzanares, Xander R., Beijer, Joshua, George, Jacob D., Mills, Dylan P., Ziebold, Josh J, Chambers, Paige, Montoya, Michael, Cheang, Nathan M., Anderson, Hunter J., Duncan, Sheridan J., Ehrlich, Lauren, Hudson, Nathan C., Kiechlin, Jack L., Koch, Will, Lee, Justin, Menassa, Dominic, Oakes, S. H., Petersen, Audrey J., Bunsow, J. R. Ramirez, Bay, Joshua, Ramirez, Sacha, Fenwick, Logan D., Boyle, Aidan P., Hibbard, Lea Pearl, Haubrich, Calder, Sherry, Daniel P., Jenkins, Josh, Furney, Sebastian, Velamala, Anjali A., Krueger, Davis J., Thompson, William N., Chhetri, Jenisha, Lee, Alexis Ying-Shan, Ray, Mia G. V., Recchia, John C., Lengerich, Dylan, Taulman, Kyle, Romero, Andres C., Steward, Ellie N., Russell, Sloan, Hardwick, Dillon F., Wootten, Katelynn, Nguyen, Valerie A., Quispe, Devon, Ragsdale, Cameron, Young, Isabel, Atchley-Rivers, N. S., Stribling, Jordin L., Gentile, Julia G, Boeyink, Taylor A., Kwiatkowski, Daniel, Dupeyron, Tomi Oshima, Crews, Anastasia, Shuttleworth, Mitchell, Dresdner, Danielle C., Flackett, Lydia, Haratsaris, Nicholas, Linger, Morgan I, Misener, Jay H., Patti, Samuel, Pine, Tawanchai P., Marikar, Nasreen, Matessi, Giorgio, Routledge, Allie C., Alkaabi, Suhail, Bartman, Jessica L., Bisacca, Gabrielle E., Busch, Celeste, Edwards, Bree, Staudenmier, Caitlyn, Starling, Travis, McVey, Caden, Montano, Maximus, Contizano, Charles J., Taylor, Eleanor, McIntyre, James K., Victory, Andrew, McCammon, Glen S., Kimlicko, Aspen, Sheldrake, Tucker, Shelchuk, Grace, Von Reich, Ferin J., Hicks, Andrew J., O'neill, Ian, Rossman, Beth, Taylor, Liam C., MacDonald, William, Becker, Simone E., Han, Soonhee, O'Sullivan, Cian, Wilcove, Isaac, Brennan, David J., Hanley, Luke C., Hull, Owen, Wilson, Timothy R., Kalmus, Madison H., Berv, Owen A., Harris, Logan Swous, Doan, Chris H, Londres, Nathan, Parulekar, Anish, Adam, Megan M., Angwin, Abigail, Cabbage, Carter C., Colleran, Zachary, Pietras, Alex, Seux, Octave, Oros, Ryan, Wilkinson, Blake C., Nguyen, Khoa D, Trank-Greene, Maedee, Barone, Kevin M., Snyder, G. L., Biehle, Samuel J, Billig, Brennen, Almquist, Justin Thomas, Dixon, Alyssa M., Erickson, Benjamin, Evans, Nathan, Genne, SL, Kelly, Christopher M, Marcus, Serafima M., Ogle, Caleb, Patel, Akhil, Vendetti, Evan, Courtney, Olivia, Deel, Sean, Del Foco, Leonardo, Gjini, Michael, Haines, Jessica, Hoff, Isabelle J., Jones, M. R., Killian, Dominic, Kuehl, Kirsten, Kuester, Chrisanne, Lantz, Maxwell B., Lee, Christian J, Mauer, Graham, McKemey, Finbar K., Millican, Sarah J., Rosasco, Ryan, Stewart, T. C., VanEtten, Eleanor, Derwin, Zachary, Serio, Lauren, Sickler, Molly G., Blake, Cassidy A., Patel, Neil S., Fox, Margaret, Gray, Michael J, Ziegler, Lucas J., Kumar, Aman Priyadarshi, Polly, Madelyn, Mesgina, Sarah, McMorris, Zane, Griffin, Kyle J., Haile, L. N., Bassel, Claire, Dixon, Thomas J., Beattie, Ryan, Houck, Timothy J, Rodgers, Maeve, Trofino, Tyson R., Lukianow, Dax, Smart, Korben, Hall, Jacqueline L., Bone, Lauren, Baldwin, James O., Doane, Connor, Almohsen, Yousef A., Stamos, Emily, Acha, Iker, Kim, Jake, Samour II, Antonio E., Chavali, S., Kanokthippayakun, Jeerakit, Gotlib, Nicholas, Murphy, Ryan C., Archibald, Jack. W., Brimhall, Alexander J, Boyer, Aidan, Chapman, Logan T., Chadda, Shivank, Sibrell, Lisa, Vallery, Mia M., Conroy, Thomas C., Pan, Luke J., Balajonda, Brian, Fuhrman, Bethany E. S., Alkubaisi, Mohamed, Engelstad, Jacob, Dodrill, Joshua, Fuchs, Calvin R., Bullard-Connor, Gigi, Alhuseini, Isehaq, Zygmunt, James C., Sipowicz, Leo, Hayrynen, Griffin A., McGill, Riley M., Keating, Caden J., Hart, Omer, Cyr, Aidan St., Steinsberger, Christopher H., Thoman, Gerig, Wood, Travis M., Ingram, Julia A., Dominguez, J., Georgiades, Nathaniel James, Johnson, Matthew, Johnson, Sawyer, Pedersen, Alexander J., Ralapanawe, Anoush K, Thomas, Jeffrey J., Sato, Ginn A., Reynolds, Hope, Nasser, Liebe, Mizzi, Alexander Z., Damgaard, Olivia, Baflah, Abdulrahman A., Liu, Steven Y., Salindeho, Adam D., Norden, Kelso, Gearhart, Emily E., Krajnak, Zack, Szeremeta, Philip, Amos, Meggan, Shin, Kyungeun, Muckenthaler, Brandon A., Medialdea, Melissa, Beach, Simone, Wilson, Connor B., Adams, Elena R, Aldhamen, Ahmed, Harris, Coyle M., Hesse, Troy M., Golding, Nathan T., Larter, Zachary, Hernandez, Angel, Morales, Genaro, Traxler, Robert B., Alosaimi, Meshal, Fitton, Aidan F., Aaron, James Holland, Lee, Nathaniel F., Liao, Ryan Z., Chen, Judy, French, Katherine V., Loring, Justin, Colter, Aurora, McConvey, Rowan, Colozzi, Michael, Vann, John D., Scheck, Benjamin T., Weigand, Anthony A, Alhabeeb, Abdulelah, Idoine, Yolande, Woodard, Aiden L., Medellin, Mateo M., Ratajczyk, Nicholas O, Tobin, Darien P., Collins, Jack C., Horning, Thomas M., Pellatz, Nick, Pitten, John, Lordi, Noah, Patterson, Alyx, Hoang, Thi D, Zimmermann, Ingrid H, Wang, Hongda, Steckhahn, Daniel, Aradhya, Arvind J., Oliver, Kristin A., Cai, Yijian, Wang, Chaoran, Yegovtsev, Nikolay, Wu, Mengyu, Ganesan, Koushik, Osborne, Andrew, Wickenden, Evan, Meyer, Josephine C., Chaparro, David, Visal, Aseem, Liu, Haixin, Menon, Thanmay S., Jin, Yan, Wilson, John, Erikson, James W., Luo, Zheng, Shitara, Nanako, Nelson, Emma E, Geerdts, T. R., Ortiz, Jorge L Ramirez, and Lewandowski, H. J.
- Subjects
Astrophysics - Solar and Stellar Astrophysics - Abstract
Flare frequency distributions represent a key approach to addressing one of the largest problems in solar and stellar physics: determining the mechanism that counter-intuitively heats coronae to temperatures that are orders of magnitude hotter than the corresponding photospheres. It is widely accepted that the magnetic field is responsible for the heating, but there are two competing mechanisms that could explain it: nanoflares or Alfv\'en waves. To date, neither can be directly observed. Nanoflares are, by definition, extremely small, but their aggregate energy release could represent a substantial heating mechanism, presuming they are sufficiently abundant. One way to test this presumption is via the flare frequency distribution, which describes how often flares of various energies occur. If the slope of the power law fitting the flare frequency distribution is above a critical threshold, $\alpha=2$ as established in prior literature, then there should be a sufficient abundance of nanoflares to explain coronal heating. We performed $>$600 case studies of solar flares, made possible by an unprecedented number of data analysts via three semesters of an undergraduate physics laboratory course. This allowed us to include two crucial, but nontrivial, analysis methods: pre-flare baseline subtraction and computation of the flare energy, which requires determining flare start and stop times. We aggregated the results of these analyses into a statistical study to determine that $\alpha = 1.63 \pm 0.03$. This is below the critical threshold, suggesting that Alfv\'en waves are an important driver of coronal heating., Comment: 1,002 authors, 14 pages, 4 figures, 3 tables, published by The Astrophysical Journal on 2023-05-09, volume 948, page 71
- Published
- 2023
- Full Text
- View/download PDF
3. Does the advertisement in Swiss pharmacy windows rest on evidence-based medicine? An observational study
- Author
-
Daniel Genne, Tanja Känzig, Melisa Potterat, Thibault Corpataux, Simone Daniele Ackermann, Edouard Chaix, Andrea Gibilisco, Aurelia Portmann, Judith Roberts, Amandine Schaller, Nicolas Wenger, Oliver Wolffers, and Charles Beguelin
- Subjects
Medicine - Abstract
Objectives The aim of the study was to analyse the proportion of evidence-based medication displayed in pharmacies and compare it between the different linguistic regions of the country, at different times of the year to determine the amount of proven effective medications indirectly recommended to the public in different parts of Switzerland.Design This is an observational study conducted by medical doctors in the department of internal medicine at the Spitalzentrum Biel, Switzerland.Setting The observation took place from July 2019 to May 2020. From a total of 1800 pharmacies in Switzerland, 68 different pharmacies were selected across the 3 main linguistic regions and the medication on display in their windows were examined 4 times a year regarding their efficacy. The displays of medication with or without evidence-based efficacy were described using absolute numbers and proportions and compared between the different linguistic regions at different seasons using χ2.Participants There were no human or animal participants involved in this study.Primary and secondary outcome measures The primary outcome is the proportion of medication displayed in pharmacy windows with a proven effectiveness in medical literature. The secondary outcome was the variability of the primary outcome over time (seasonal changes), over the different linguistic regions of Switzerland and between chains and privately owned pharmacies.Results We examined 970 medications and found that over the whole year, there is a high proportion of non-evidence-based drugs (56,9%) displayed in pharmacies. Swiss German cantons display significantly more non-evidence-based medications in winter. We found no statistical difference for other seasons or between chains and privately owned pharmacies.Conclusion Pharmacies in Switzerland tend to display significantly more non-evidence-based drugs, thus indirectly recommending them to the public. In a time of necessary expansion of self-medication by the population, this could incite consumers to buy drugs without proven effectiveness.
- Published
- 2023
- Full Text
- View/download PDF
4. The Development and Analysis of a Multistage Spraying Method for Liquids in an Ultrasonic Field
- Author
-
Andrey Shalunov, Vladimir Khmelev, Sergey Terentiev, Viktor Nesterov, and Dmitry Genne
- Subjects
liquid atomization ,ultrasonic ,droplet dispersion ,spraying ,emitter ,droplet deformation ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Spraying various liquids (primarily aqueous solutions of various substances) is widely used in various technological processes. For most of them, high dispersibility and a narrow droplet size distribution are essential. Ultrasonic spraying allows these parameters to be achieved. However, the higher the dispersity of droplets produced by ultrasonic spraying, the lower the spray productivity. To solve this problem, we propose a method of multistage spraying, consisting of the generation of a large number of particles of large initial size (to ensure high productivity) and their subsequent destruction by propagation in a periodic ultrasonic field (to ensure small droplet sizes at high productivity). To experimentally determine the capabilities of this technique, a tubular emitter in the shape of a cylinder with a stepped-variable cross-section was designed. The configuration of the ultrasonic field inside the emitter (22.2 kHz; 182 dB) implements three-stage spraying (the number of sputtering stages corresponds to the number of anti-nodes along the emitter axis). The effectiveness of the proposed and developed technique, suitable for the generation of droplets smaller than 40 µm, with performance exceeding the known ultrasonic spray techniques by at least 10-fold, was confirmed in the course of the conducted research.
- Published
- 2024
- Full Text
- View/download PDF
5. Innovative Acoustic-Hydraulic Method for High-Performance Fine Liquid Atomization
- Author
-
Olga Kudryashova, Andrey Shalunov, Dmitry Genne, Roman Dorovskikh, and Sergey Titov
- Subjects
liquid atomization ,ultrasound ,acoustic-hydraulic nozzle ,droplet dispersion ,cavitation ,critical mode ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Spray technology is widely used in various industries, including medicine, food production, mechanical engineering, and nanopowder manufacturing. Achieving high dispersion and a narrow particle size distribution is crucial for many applications. Ultrasonic spraying is commonly used to achieve this. On the other hand, hydraulic nozzles provide high atomization performance. Combining these two technologies promises to offer significant benefits, but the complex processes that occur simultaneously in such a device require careful study. This work proposes a fundamental design for an acoustic-hydraulic nozzle and investigates the physical processes when a liquid is sprayed using this nozzle, both theoretically and experimentally. The study identifies the critical modes of spraying and confirms that the simultaneous use of ultrasound and hydraulic pressure can produce a fine spray (droplet size less than 50 μm vs. 150–500 μm for hydrodynamic spray) with high productivity (5–10 mL/s vs. 0.5 mL/min for ultrasonic spray). This approach has significant potential for modern industries and technologies.
- Published
- 2023
- Full Text
- View/download PDF
6. OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
- Author
-
Vachenc, Sébastien, Gobbo, Jessica, Moujarrebe, Sarah El, Desmoulins, Isabelle, Gilabert, Marine, Beau-Faller, Michelle, Mitry, Emmanuel, Girard, Nicolas, Bertaut, Aurélie, Dusetti, Nelson, Iovanna, Juan L., Yousfi, Rahima, Pierrat, Fabien, Bruno, Roman, Cueff, Adèle, Boidot, Romain, and Genne, Philippe
- Published
- 2022
- Full Text
- View/download PDF
7. OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
- Author
-
Sébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, Isabelle Desmoulins, Marine Gilabert, Michelle Beau-Faller, Emmanuel Mitry, Nicolas Girard, Aurélie Bertaut, Nelson Dusetti, Juan L. Iovanna, Rahima Yousfi, Fabien Pierrat, Roman Bruno, Adèle Cueff, Romain Boidot, and Philippe Genne
- Subjects
Early/ late resistance marker ,NGS ,Immunological profile ,Triple negative breast or Luminal Breast Cancer ,Non small-cell lung cancer ,Pancreatic ductal adenocarcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity are defined as tumor non-response which does not allow a good understanding of the diversity of the underlying mechanisms. The main objective of the OncoSNIPE® collaborative clinical research program is to identify early and late markers of resistance to treatment. Methods Multicentric, interventional study with the primary objective to identify early and / or late markers of resistance to treatment, in 600 adult patients with locally advanced or metastatic triple negative or Luminal B breast cancer, non-small-cell lung cancer or pancreatic ductal adenocarcinoma. Patients targeted in this study have all rapid progression of their pathology, making it possible to obtain models for evaluating markers of early and / or late responses over the 2-year period of follow-up, and thus provide the information necessary to understand resistance mechanisms. To explore the phenomena of resistance, during therapeutic response and / or progression of the pathology, we will use a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq), clinical data, medical images and immunological profile by ELISA. Patients will have long-term follow-up with different biological samples, at baseline (blood and biopsy) and at each tumoral evaluation or tumoral progression evaluated by medical imaging. Clinical data will be collected through a dedicated Case Report Form (CRF) and enriched by semantic extraction based on the French ConSoRe (Continuum Soins Recherche) initiative, a dedicated Semantic Clinical Data Warehouse (SCDW) to cancer. The study is sponsored by Oncodesign (Dijon, France) and is currently ongoing. Discussion The great diversity of intrinsic or acquired molecular mechanisms involved in resistance to treatment constitutes a real therapeutic issue. Improving understanding of mechanisms of resistance of cancer cells to anti-tumor treatments is therefore a major challenge. The OncoSNIPE cohort will lead to a better understanding of the mechanisms of resistance and will allow to explore new mechanisms of actions and to discover new therapeutic targets or strategies making it possible to circumvent the escape in different types of cancer. Trial registration Clinicaltrial.gov. Registered 16 September 2020, https://clinicaltrials.gov/ct2/show/NCT04548960?term=oncosnipe&draw=2&rank=1 and ANSM ID RCB 2017-A02018-45.
- Published
- 2022
- Full Text
- View/download PDF
8. METHOD AND MEANS OF TESTING CAVITATION EROSION UNDER ABNORMAL CONDITIONS
- Author
-
Vladimir N. Khmelev, Roman V. Barsukov, Roman N. Golykh, Denis S. Abramenko, Dmitry V. Genne, and Pavel P. Tertishnikov
- Subjects
ultrasonic impact ,acoustic field ,erosion ,extreme conditions ,frequency ,normal conditions ,amplitude ,Engineering geology. Rock mechanics. Soil mechanics. Underground construction ,TA703-712 - Abstract
The relevance of the research is caused by the need to study the resistance of metals and their coatings to cavitation erosion in conditions of abnormally high temperatures, pressures, as well as in chemically aggressive environments in the form of acids, alkalis or aggressive gases (such as ozone). The main aim of the research is to develop specialized equipment for monitoring and detecting modes and dependencies of cavitation destruction of various metals and their coatings at abnormally high temperatures and overpressure, as well as methodology for determining (controlling) the resistance of metals and their coatings in cavitation fields. Objects: testing cavitation erosion under abnormal conditions using specially designed ultrasonic equipment for this task. Method: experimental method for studying cavitation erosion under abnormal conditions. This method is the development of the existing one regulated by the ASTM G32-10 «Standard test method for cavitation erosion». Results. To create, research and apply special materials and coatings that can ensure long-term reliable equipment operation the authors have proposed and developed a new method for monitoring the erosion resistance of metals and protective coatings under cavitation exposure in abnormal operating conditions, in terms of pressure and temperature. This method expands the capabilities of the ASTM G32-10 «Standard test method for cavitation erosion». Practical implementation of tests of cavitation erosion of metals and protective coatings under abnormal conditions will ensure the creation and application of new materials for use in various branches of human activity and industry.
- Published
- 2021
- Full Text
- View/download PDF
9. Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
- Author
-
Hayley Cassidy, Mart van Genne, Erley Lizarazo-Forero, Hubert G. M. Niesters, and Lilli Gard
- Subjects
QIAstat-Dx ,BioFire FilmArray ,molecular diagnostics ,respiratory infections ,syndromic testing ,point-of-care (POC) ,Microbiology ,QR1-502 - Abstract
Point-of-care syndromic panels allow for simultaneous and rapid detection of respiratory pathogens from nasopharyngeal swabs. The clinical performance of the QIAstat-Dx Respiratory SARS-CoV-2 panel RP2.0 (QIAstat-Dx RP2.0) and the BioFire FilmArray Respiratory panel RP2.1 (BioFire RP2.1) was evaluated for the detection of SARS-CoV-2 and other common respiratory pathogens. A total of 137 patient samples were retrospectively selected based on emergency department admission, along with 33 SARS-CoV-2 positive samples tested using a WHO laboratory developed test. The limit of detection for SARS-CoV-2 was initially evaluated for both platforms. The QIAstat-Dx RP2.0 detected SARS-CoV-2 at 500 copies/mL and had a positive percent agreement (PPA) of 85%. The BioFire RP2.1 detected SARS-CoV-2 at 50 copies/mL and had a PPA of 97%. Both platforms showed a negative percent agreement of 100% for SARS-CoV-2. Evaluation of analytical specificity from a range of common respiratory targets showed a similar performance between each platform. The QIAstat-Dx RP2.0 had an overall PPA of 82% (67–100%) in clinical samples, with differences in sensitivity depending on the respiratory target. Both platforms can be used to detect acute cases of SARS-CoV-2. While the QIAstat-Dx RP2.0 is suitable for detecting respiratory viruses within a clinical range, it has less analytical and clinical sensitivity for SARS-CoV-2 compared to the BioFire RP2.1.
- Published
- 2022
- Full Text
- View/download PDF
10. Coronal Heating as Determined by the Solar Flare Frequency Distribution Obtained by Aggregating Case Studies
- Author
-
James Paul Mason, Alexandra Werth, Colin G. West, Allison Youngblood, Donald L. Woodraska, Courtney L. Peck, Arvind J. Aradhya, Yijian Cai, David Chaparro, James W. Erikson, Koushik Ganesan, T. R. Geerdts, Thi D Hoang, Thomas M. Horning, Yan Jin, Haixin Liu, Noah Lordi, Zheng Luo, Thanmay S. Menon, Josephine C. Meyer, Emma E Nelson, Kristin A. Oliver, Jorge L Ramirez Ortiz, Andrew Osborne, Alyx Patterson, Nick Pellatz, John Pitten, Nanako Shitara, Daniel Steckhahn, Aseem Visal, Hongda Wang, Chaoran Wang, Evan Wickenden, John Wilson, Mengyu Wu, Nikolay Yegovtsev, Ingrid H Zimmermann, James Holland Aaron, Jumana T. Abdullah, Jonathan M. Abrams, Riley Abrashoff, Andres B. Acevedo, Iker Acha, Daniela M. Meza Acosta, Megan M. Adam, Dante Q. Adams, Kalvyn N Adams, Elena R Adams, Zainab A. Akbar, Ushmi H. Akruwala, Adel Al-Ghazwi, Batool H. Alabbas, Areej A. Alawadhi, Yazeed A. Alharbi, Mohammed S. Alahmed, Mohammed A. Albakr, Yusef J. Albalushi, Jonathan Albaum, Ahmed Aldhamen, Nolan Ales, Mohammad Alesmail, Abdulelah Alhabeeb, Dania Alhamli, Isehaq Alhuseini, Suhail Alkaabi, Tameem Alkhezzi, Mohamed Alkubaisi, Nasser Allanqawi, Martin Allsbrook, Yousef A. Almohsen, Justin Thomas Almquist, Teeb Alnaji, Yousef A Alnasrallah, Nicholas Alonzi, Meshal Alosaimi, Emeen Alqabani, Mohammad Alrubaie, Reema A. Alsinan, Ava L. Altenbern, Abdullah Altokhais, Saleh A. Alyami, Federico Ameijenda, Hamzi Amer, Meggan Amos, Hunter J. Anderson, Carter Andrew, Jesse C Andringa, Abigail Angwin, Gabreece Van Anne, Andrew Aramians, Camila Villamil Arango, Jack. W. Archibald, Brian A. Arias-Robles, Maryam Aryan, Kevin Ash, Justin Astalos, N. S. Atchley-Rivers, Dakota N. Augenstein, Bryce W. Austin, Abhinav Avula, Matthew C. Aycock, Abdulrahman A. Baflah, Sahana Balaji, Brian Balajonda, Leo M Balcer, James O. Baldwin, David J Banda, Titus Bard, Abby Barmore, Grant M. Barnes, Logan D. W. Barnhart, Kevin M. Barone, Jessica L. Bartman, Claire Bassel, Catalina S Bastias, Batchimeg Bat-Ulzii, Jasleen Batra, Lexi Battist, Joshua Bay, Simone Beach, Sara Beard, Quinn I Beato, Ryan Beattie, Thomas Beatty, Tristan De La Beaujardiere, Jacob N. Beauprez, M. G. Beck, Lily Beck, Simone E. Becker, Braden Behr, Timothy A. Behrer, Joshua Beijer, Brennan J. Belei, Annelene L. Belknap, Aislyn Bell, Caden Bence, Evan Benke, Naomi Berhanu, Zachary D. Berriman-Rozen, Chrisanna Bertuccio, Owen A. Berv, Blaine B. Biediger, Samuel J Biehle, Brennen Billig, Jacob Billingsley, Jayce A. Billman, Connor J. Biron, Gabrielle E. Bisacca, Cassidy A. Blake, Guillermo Blandon, Olivia Blevins, Ethan Blouin, Michal Bodzianowski, Taylor A. Boeyink, Matthew Bondar, Lauren Bone, Alberto Espinosa De Los Monteros Bonilla, William T Borelli, Luke R. Borgerding, Troy Bowen, Christine Boyer, Aidan Boyer, Aidan P. Boyle, Tom Boyne, Donovan Branch, Ariana E. Brecl, David J. Brennan, Alexander J Brimhall, Jennifer L. Brockman, Sarah Brookins, Gabriel T. Brown, Cameron L. Brown, Ryan Brown, Jordi Brownlow, Grant Brumage-Heller, Preston J. Brumley, Samuel Bryan, A. Brzostowicz, Maryam Buhamad, Gigi Bullard-Connor, J. R. Ramirez Bunsow, Annemarie C. Burns, John J. Burritt, Nicholas David Burton, Taylor Burton, Celeste Busch, Dylan R. Butler, B. W. Buxton, Malena C. Toups, Carter C. Cabbage, Breonna Cage, Jackson R. Cahn, Andrew J Campbell, Braden P. Canales, Alejandro R. Cancio, Luke Carey, Emma L. Carillion, Michael Andrew Carpender, Emily Carpenter, Shivank Chadda, Paige Chambers, Jasey Chanders, Olivia M. Chandler, Ethan C. Chang, Mitchell G. Chapman, Logan T. Chapman, S. Chavali, Luis Chavez, Kevin Chen, Lily Chen, Sam Chen, Judy Chen, Jenisha Chhetri, Bradyn Chiles, Kayla M. Chizmar, Katherine E Christiansen, Nicholas A. Cisne, Alexis Cisneros, David B. Clark, Evelyn Clarke, Peter C Clarkson, Alexis R. Clausi, Brooke Cochran, Ryan W. Coe, Aislinn Coleman-Plante, Jake R. Colleran, Zachary Colleran, Curran Collier, Nathaniel A. Collins, Sarah Collins, Jack C. Collins, Michael Colozzi, Aurora Colter, Rebecca A. Cone, Thomas C. Conroy, Reese Conti, Charles J. Contizano, Destiny J. Cool, Nicholas M. Cooper, Jessica S Corbitt, Jonas Courtney, Olivia Courtney, Corben L. Cox, Wilmsen B. Craig, Joshua B. Creany, Anastasia Crews, K. A. Crocker, A. J. Croteau, Christian J. Crow, Zoe Cruse, Avril Cruz, Tyler L. Curnow, Hayden Current, Riley T. Curry, Libby Cutler, Aidan St. Cyr, Frederick M. Dabberdt, Johnston Daboub, Olivia Damgaard, Swagatam Das, Emma A. B. Davis, Elyse Debarros, Sean Deel, Megan E. Delasantos, Tianyue Deng, Zachary Derwin, Om Desai, Kai Dewey, John S. Dias, Kenzie A. Dice, R. Dick, Cyrus A. Dicken, Henry Dietrick, Alexis M. Dinser, Alyssa M. Dixon, Thomas J. Dixon, Helen C. Do, Chris H Doan, Connor Doane, Joshua Dodrill, Timothy Doermer, Lizbeth Montoya Dominguez, J. Dominguez, Emerson N. Domke, Caroline R. Doran, Jackson A. Dorr, Philip Dorricott, Danielle C. Dresdner, Michael Driscoll, Kailer H. Driscoll, Sheridan J. Duncan, Christian Dunlap, Gabrielle M. Dunn, Tien Q. Duong, Tomi Oshima Dupeyron, Peter Dvorak, Andrew East, Andrew N. East, Bree Edwards, Lauren Ehrlich, Sara I. Elbashir, Rasce Engelhardt, Jacob Engelstad, Colin England, Andrew Enrich, Abbey Erickson, Benjamin Erickson, Nathan Evans, Calvin A Ewing, Elizabeth A. Eyeson, Ian Faber, Avery M. Fails, John T Fauntleroy, Kevin Fell, Zitian Feng, Logan D. Fenwick, Nikita Feoktistov, Ryann Fife, John Alfred D. Figueirinhas, Jean-Paul Fisch, Emmalee Fischer, Jules Fischer-White, Aidan F. Fitton, Alexander Fix, Lydia Flackett, Fernando Flores, Aidan Floyd, Leonardo Del Foco, Adeduni Folarin, Aidan E. Forbes, Elise Fortino, Benjamin L. Fougere, Alexandra A. Fowler, Margaret Fox, James M. French, Katherine V. French, Florian G. Frick, Calvin R. Fuchs, Bethany E. S. Fuhrman, Sebastian Furney, Moutamen Gabir, Gabriela Galarraga, Skylar Gale, Keala C. Gapin, A. J. Garscadden, Rachel Gasser, Lily Gayou, Emily E. Gearhart, Jane Geisman, Julianne R. Geneser, Sl Genne, Julia G Gentile, Eleanor Gentry, Jacob D. George, Nathaniel James Georgiades, Phillip Gerhardstein, Clint Gersabeck, Bandar Abu Ghaith, Dorsa Ghiassi, B. C. Giebner, Dalton Gilmartin, Connor B. Gilpatrick, Michael Gjini, Olivia Golden, Nathan T. Golding, C. A. Goldsberry, Angel R. Gomez, Angel A. Gomez, Sean Gopalakrishnan, Mariam Gopalani, Nicholas Gotlib, Alaina S. Graham, Michael J Gray, Alannah H. Gregory, Joshua A. Gregory, Kristyn Grell, Justus Griego, Nicholas F. Griffin, Kyle J. Griffin, Matt Guerrero, Nicole Gunderson, Mutian Guo, E. R. Gustavsson, Grace K. Hach, L. N. Haile, Jessica Haines, Jack J. Mc Hale, Ryder Buchanan Hales, Mark S. Haley, Jacqueline L. Hall, Sean R. Hamilton, Soonhee Han, Tyler Hand, Luke C. Hanley, Connor M Hansen, Joshua A. Hansen, Jonathan Hansson, Tony Yunfei Hao, Nicholas Haratsaris, Isabelle Hardie, Dillon F. Hardwick, Cameron T. Hares, Logan Swous Harris, Coyle M. Harris, Omer Hart, Kyle Hashiro, Elsie Hattendorf, Calder Haubrich, Elijah Hawat, Griffin A. Hayrynen, Danielle A. Heintz, Tim Hellweg, Angel Hernandez, Emanuel Herrera, Robert N. Herrington, Tim Herwig, Troy M. Hesse, Quinn Hiatt, Lea Pearl Hibbard, Imari R. Hicks, Andrew J. Hicks, Nigel Highhouse, Annalise K. Hildebrand, Paula Hill, Hallie Hill, Evan Hintsa, Anna E. Hirschmann, Travis Hitt, Ella Ho, Isabelle J. Hoff, Alex Hoffman, Blake A. Hogen, Linda Horne, Timothy J Houck, Noah H. Howell, E. M. Hrudka, J. Hu, Jianyang Huang, Chenqi Huang, Shancheng Huang, Zachary A. Hudson, Nathan C. Hudson, Tyler J. Huebsch, Owen Hull, Samuel C Hunter, Troy Husted, Abigail P. Hutabarat, Leslie Huynh, Antonio E. Samour Ii, Yolande Idoine, Julia A. Ingram, Taro Iovan, Samuel A. Isert, Antonio Salcido-Alcontar Jr, Thomas Jacobsen, Alan A Jaimes, Connor Jameson, J. R. Jarriel, Sam Jarvis, Josh Jenkins, Alexander V. Jensen, Jacob Jeong, Luke A. Jeseritz, Trevor Jesse, Soo Yeun Ji, Yufan Jiang, Owen Johnson, Matthew Johnson, Sawyer Johnson, Julia Johnston, Braedon Y. Johnston, Olivia M. Jones, M. R. Jones, Tara Jourabchi, Tony A. House Jr., Parker Juels, Sabrina J. H. T. Kainz, Emily Kaiser, Nicolas Ian Kallemeyn, Madison H. Kalmus, Etash Kalra, Margaret Kamenetskiy, Jeerakit Kanokthippayakun, Shaun D. Kapla, Brennan J. Karsh, Caden J. Keating, Morgan A. Kelley, Michael P. Kelley, Nicholas Kelly, James Kelly, Teagan Kelly, Christopher M Kelly, Kellen Kennedy, Cayla J. Kennedy, Forrest Kennedy, Abigail Kennedy, Liana Kerr-Layton, Marilyn Ketterer, Ibraheem A. Khan, Usman Khan, Sapriya Khanal, Jack L. Kiechlin, Dominic Killian, Kevin Kim, Brian T. Kim, Matthew M. Kim, Jake Kim, Aspen Kimlicko, Isabel M Kipp, Hunter B. Kirkpatrick, Natalie Kissner, Emily R. Kite, Olivia R. Kleinhaus, Philip Whiting Knott, Will Koch, Greta Koenig, Emily Koke, Thomas Kokes, Yash S. Kothamdi, Zack Krajnak, Zoe M. Kresek, Dylan Kriegman, Jake E. Kritzberg, Davis J. Krueger, Bartlomiej Kubiak, Kirsten Kuehl, Chrisanne Kuester, Nicolas A. Kuiper, Aman Priyadarshi Kumar, Connor Kuybus, Daniel Kwiatkowski, Quintin Y. Lafemina, Kevin Lacjak, Kyle Lahmers, Antonia Lam, Kalin Landrey, Maxwell B. Lantz, Zachary Larter, Benjamin P. Lau, Megan Lauzon, Rian Lawlor, Tyler Learned, E. C. Lee, Junwon Lee, Adrianna J. Lee, Justin Lee, Alexis Ying-Shan Lee, Christian J Lee, Nathaniel F. Lee, Linzhi Leiker, Dylan Lengerich, Cecilia Leoni, Adrienne R. Lezak, David Y. Li, Isaac Li, Ryan Z. Liao, Bridget Linders, Morgan I Linger, Katherine B. Linnane, Sam Lippincott, Barrett Lister, Shelby D Litton, Nianzi Liu, Steven Y. Liu, Timothy W. Logan, Nathan Londres, Mia C. Lonergan, Emily Lookhoff, N. E. Loomis, Christian Lopez, Justin Loring, Jeffrey Lucca, Dax Lukianow, Nathan M. Cheang, William Macdonald, Claire A. Madonna, Kasey O. Madsen, Tiffany E. Maksimuk, Macguire Mallory, Ryan A. Malone, Blake Maly, Xander R. Manzanares, Aimee S. Maravi, Serafima M. Marcus, Nasreen Marikar, Josie A. Marquez, Mathew J. Marquez, Lauren Marsh, Toni Marsh, Logan S. Martin, Alexa M. Martinez, Jose R. Martinez, Hazelia K. Martinez, Cara Martyr, Mirna Masri, Giorgio Matessi, Adam Izz Khan Mohd Reduan Mathavan, Randi M. Mathieson, Kabir P. Mathur, Graham Mauer, Victoria A. Mayer, Liam Mazzotta, Glen S. Mccammon, Rowan Mcconvey, Tyler Mccormick, Andrew Mccoy, Kelleen Mcentee, Meaghan V. Mcgarvey, Riley M. Mcgill, James K. Mcintyre, Finbar K. Mckemey, Zane Mcmorris, Jesse J. Mcmullan, Ella Mcquaid, Caden Mcvey, Kyle Mccurry, Mateo M. Medellin, Melissa Medialdea, Amar Mehidic, Stella Meillon, Jonah B. Meiselman-Ashen, Sarah Mellett, Dominic Menassa, Citlali Mendez, Patricia Mendoza-Anselmi, Riley Menke, Sarah Mesgina, William J. Mewhirter, Ethan Meyer, Aya M. Miften, Ethan J. Miles, Andrew Miller, Joshua B. Miller, Emily B. Millican, Sarah J. Millican, Dylan P. Mills, Josh Minimo, Jay H. Misener, Alexander J. Mitchell, Alexander Z. Mizzi, Luis Molina-Saenz, Tyler S Moll, Hayden Moll, Maximus Montano, Michael Montoya, Eli Monyek, Jacqueline Rodriguez Mora, Gavin Morales, Genaro Morales, Annalise M. Morelock, Cora Morency, Angel J. Moreno, Remy Morgan, Alexander P. Moss, Brandon A. Muckenthaler, Alexander Mueller, Owen T. Mulcahy, Aria T. Mundy, Alexis A. Muniz, Maxwell J. Murphy, Madalyn C. Murphy, Ryan C. Murphy, Tyler Murrel, Andrew J. Musgrave, Michael S. Myer, Kshmya Nandu, Elena R. Napoletano, Abdulaziz Naqi, Anoothi Narayan, Liebe Nasser, Brenna K Neeland, Molly Nehring, Maya Li Nelson, Lena P. Nguyen, Lena Nguyen, Leonardo Nguyen, Valerie A. Nguyen, Khoa D Nguyen, Kelso Norden, Cooper Norris, Dario Nuñez, Rosemary O. Nussbaum, Cian O’Sullivan, Ian O’Neill, S. H. Oakes, Anand Odbayar, Caleb Ogle, Sean Oishi-Holder, Nicholas Olguin, Nathaniel P. Olson, Jason Ong, Elena N. Opp, Dan Orbidan, Ryan Oros, Althea E. Ort, Matthew Osborn, Austin Osogwin, Grant Otto, Jessica Oudakker, Igor Overchuk, Hannah M. Padgette, Jacqueline Padilla, Mallory Palizzi, Madeleine L. Palmgren, Adler Palos, Luke J. Pan, Nathan L. Parker, Sasha R. Parker, Evan J. Parkinson, Anish Parulekar, Paige J. Pastor, Kajal Patel, Akhil Patel, Neil S. Patel, Samuel Patti, Catherine Patton, Genevieve K. Payne, Matthew P. Payne, Harrison M. Pearl, Charles B. Beck Von Peccoz, Alexander J. Pedersen, Lily M. Pelster, Munisettha E. Peou, J. S. Perez, Freddy Perez, Anneliese Pesce, Audrey J. Petersen, B. Peterson, Romeo S. L. Petric, Joshua Pettine, Ethan J. Phalen, Alexander V. Pham, Denise M. Phan, Callie C Pherigo, Lance Phillips, Justin Phillips, Krista Phommatha, Alex Pietras, Tawanchai P. Pine, Sedique Pitsuean-Meier, Andrew M. Pixley, Will Plantz, William C. Plummer, Kaitlyn E. Plutt, Audrey E. Plzak, Kyle Pohle, Hyden Polikoff, Matthew Pollard, Madelyn Polly, Trevor J. Porter, David Price, Nicholas K. Price, Gale H. Prinster, Henry Austin Propper, Josh Quarderer, Megan S. Quinn, Oliver Quinonez, Devon Quispe, Cameron Ragsdale, Anna L. Rahn, M. Rakhmonova, Anoush K Ralapanawe, Nidhi Ramachandra, Nathaniel Ramirez, Ariana C. Ramirez, Sacha Ramirez, Parker Randolph, Anurag Ranjan, Frederick C Rankin, Sarah Grace Rapaport, Nicholas O Ratajczyk, Mia G. V. Ray, Brian D. Reagan, John C. Recchia, Brooklyn J. Reddy, Joseph Reed, Charlie Reed, Justin Reeves, Eileen N. Reh, Ferin J. Von Reich, Andrea B. Reyna, Alexander Reynolds, Hope Reynolds, Matthew Rippel, Guillermo A. Rivas, Anna Linnea Rives, Amanda M. Robert, Samuel M. Robertson, Maeve Rodgers, Stewart Rojec, Andres C. Romero, Ryan Rosasco, Beth Rossman, Michael Rotter, Tyndall Rounsefell, Charlotte Rouse, Allie C. Routledge, Marc G. Roy, Zoe A. Roy, Ryan Ruger, Kendall Ruggles-Delgado, Ian C. Rule, Madigan Rumley, Brenton M. Runyon, Collin Ruprecht, Bowman Russell, Sloan Russell, Diana Ryder, David Saeb, J. Salazar, Violeta Salazar, Maxwell Saldi, Jose A. Salgado, Adam D. Salindeho, Ethan S. Sanchez, Gustavo Sanchez-Sanchez, Darian Sarfaraz, Sucheta Sarkar, Ginn A. Sato, Carl Savage, Marcus T. Schaller, Benjamin T. Scheck, Jared A. W. Schlenker, Matthew J Schofer, Stephanie H. Schubert, Courtney Schultze, Grace K Schumacher, Kasper Seglem, Lauren Serio, Octave Seux, Hannan Shahba, Callie D. Shannahan, Shajesh Sharma, Nathan Shaver, Timothy Shaw, Arlee K. Shelby, Emma Shelby, Grace Shelchuk, Tucker Sheldrake, Daniel P. Sherry, Kyle Z. Shi, Amanda M. Shields, Kyungeun Shin, Michael C. Shockley, Dominick Shoha, Jadon Shortman, Mitchell Shuttleworth, Lisa Sibrell, Molly G. Sickler, Nathan Siles, H. K. Silvester, Conor Simmons, Dylan M. Simone, Anna Simone, Savi Singh, Maya A. Singh, Madeline Sinkovic, Leo Sipowicz, Chris Sjoroos, Ryan Slocum, Colin Slyne, Korben Smart, Alexandra N. Smith, Kelly Smith, Corey Smith, Elena K. Smith, Samantha M. Smith, Percy Smith, Trevor J Smith, G. L. Snyder, Daniel A. Soby, Arman S. Sohail, William J. Solorio, Lincoln Solt, Caitlin Soon, Ava A Spangler, Benjamin C. Spicer, Ashish Srivastava, Emily Stamos, Peter Starbuck, Ethan K. Stark, Travis Starling, Caitlyn Staudenmier, Sheen L. Steinbarth, Christopher H. Steinsberger, Tyler Stepaniak, Ellie N. Steward, Trey Stewart, T. C. Stewart, Cooper N. Stratmeyer, Grant L. Stratton, Jordin L. Stribling, S. A Sulaiman, Brandon J Sullivan, M. E. Sundell, Sohan N. Sur, Rohan Suri, Jason R. Swartz, Joshua D. Sweeney, Konner Syed, Emi Szabo, Philip Szeremeta, Michael-Tan D. Ta, Nolan C. Tanguma, Kyle Taulman, Nicole Taylor, Eleanor Taylor, Liam C. Taylor, K. E. Tayman, Yesica Tellez, Richard Terrile, Corey D Tesdahl, Quinn N. Thielmann, Gerig Thoman, Daniel Thomas, Jeffrey J. Thomas, William N. Thompson, Noah R. Thornally, Darien P. Tobin, Kelly Ton, Nathaniel J. Toon, Kevin Tran, Bryn Tran, Maedee Trank-Greene, Emily D. Trautwein, Robert B. Traxler, Judah Tressler, Tyson R. Trofino, Thomas Troisi, Benjamin L. Trunko, Joshua K. Truong, Julia Tucker, Thomas D Umbricht, C. H. Uphoff, Zachary T. Upthegrove, Shreenija Vadayar, Whitney Valencia, Mia M. Vallery, Eleanor Vanetten, John D. Vann, Ilian Varela, Alexandr Vassilyev, Nicholas J. Vaver, Anjali A. Velamala, Evan Vendetti, Nancy Ortiz Venegas, Aditya V. Vepa, Marcus T. Vess, Jenna S. Veta, Andrew Victory, Jessica Vinson, Connor Maklain Vogel, Michaela Wagoner, Steven P. Wallace, Logan Wallace, Caroline Waller, Jiawei Wang, Keenan Warble, N. R. D. Ward-Chene, James Adam Watson, Robert J. Weber, Aidan B. Wegner, Anthony A Weigand, Amanda M. Weiner, Ayana West, Ethan Benjamin Wexler, Nicola H. Wheeler, Jamison R. White, Zachary White, Oliver S. White, Lloyd C. Whittall, Isaac Wilcove, Blake C. Wilkinson, John S. Willard, Abigail K. Williams, Sajan Williams, Orion K. Wilson, Evan M. Wilson, Timothy R. Wilson, Connor B. Wilson, Briahn Witkoff, Aubrey M. Wolfe, Jackson R. Wolle, Travis M. Wood, Aiden L. Woodard, Katelynn Wootten, Catherine Xiao, Jianing Yang, Zhanchao Yang, Trenton J. Young, Isabel Young, Thomas Zenner, Jiaqi Zhang, Tianwei Zhao, Tiannie Zhao, Noah Y. Zhao, Chongrui Zhou, Josh J Ziebold, Lucas J. Ziegler, James C. Zygmunt, Jinhua Zhang, and H. J. Lewandowski
- Subjects
Solar physics ,Solar flares ,Astrostatistics distributions ,Astrophysics ,QB460-466 - Abstract
Flare frequency distributions represent a key approach to addressing one of the largest problems in solar and stellar physics: determining the mechanism that counterintuitively heats coronae to temperatures that are orders of magnitude hotter than the corresponding photospheres. It is widely accepted that the magnetic field is responsible for the heating, but there are two competing mechanisms that could explain it: nanoflares or Alfvén waves. To date, neither can be directly observed. Nanoflares are, by definition, extremely small, but their aggregate energy release could represent a substantial heating mechanism, presuming they are sufficiently abundant. One way to test this presumption is via the flare frequency distribution, which describes how often flares of various energies occur. If the slope of the power law fitting the flare frequency distribution is above a critical threshold, α = 2 as established in prior literature, then there should be a sufficient abundance of nanoflares to explain coronal heating. We performed >600 case studies of solar flares, made possible by an unprecedented number of data analysts via three semesters of an undergraduate physics laboratory course. This allowed us to include two crucial, but nontrivial, analysis methods: preflare baseline subtraction and computation of the flare energy, which requires determining flare start and stop times. We aggregated the results of these analyses into a statistical study to determine that α = 1.63 ± 0.03. This is below the critical threshold, suggesting that Alfvén waves are an important driver of coronal heating.
- Published
- 2023
- Full Text
- View/download PDF
11. Geographical variations and correlation among some chemical and thermal properties of Almaciga (Agathis philippinensis Warb.) resins from selected commercial sites in the Philippines
- Author
-
Ramon A. Razal, Aileen A. Jara, Genne Patt O. Samar, Ralph Lauren M. Alomia, Kem M. Taghap, Marinelle R. Agonia, and Ma. Diana DM. Rendon
- Subjects
Almaciga ,Agathis philippinensis Warb. ,Diterpenoid resin acids ,Resin characterization ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Almaciga (Agathis philippinensis Warb.), a tropical conifer that is tapped for its resin commercially known as Manila copal, grows in many parts of the Philippines, but resin buyers prefer and pay a better price for resin from southern Palawan. The study was done to characterize almaciga resins obtained from commercial sites in Davao Oriental and Palawan (Brooke's Point and Marufinas) to explain the quality and price differences. Fresh and aged resin samples were subjected to wet chemical, thermal, and spectral analyses. Generally, the resin samples were found to be soluble in the more polar solvents although significant variations were observed for resins from various sites. Titrimetric determination revealed no significant variation in acid and saponification values, although the Brooke's Point resin had significantly lower unsaponifiable components. Predominant Fourier transform infrared spectroscopy (FTIR) absorption peaks for fresh resin include strong C=O stretch and weak = C–H stretch. Aged Palawan resins, which showed increased solubility in polar solvents, exhibited increased intensity of prominent FTIR peaks such as O–H stretch and C=O stretch. The weak peak at 1719 cm−1 seen in fresh Palawan resins was no longer observed in aged resins. DSC revealed the semi-crystalline nature of almaciga resin and melting temperatures similar to diterpenoid resin acids. This is attributed to the presence of increasing amounts of oxidized abietic acids as shown by gas chromatography-mass spectrometry (GCMS). For the Davao Oriental resins, significant amount of agatholic acid was shown, while resin acids of the abietane and pimarane type were conspicuously absent in the GC-MS spectrograms. The study found evidence that almaciga resins from Davao and Palawan differ in chemical composition and physical properties, which could explain the quality and price differences.
- Published
- 2021
- Full Text
- View/download PDF
12. Using Object Boxes to Teach the Form, Function, and Vocabulary of the Parts of the Human Eye
- Author
-
Rule, Audrey C. and Welch, Genne
- Abstract
These science activities for elementary students focus on the external structures and functions of the human eye with hands-on object box activities based on the Montessori theory (1966) of concrete learning through manipulation of objects and focus of attention through touch. Object boxes are sets of items and corresponding cards housed in a box. Two types of object boxes are highlighted: (a) form and function analogy object boxes that describe the structures and functions of external parts of the human eye along with analogous manufactured items exhibiting the same forms and functions and (b) words with multiple meanings object boxes that present objects and two different meanings of eye-related words. These activities use analogy to help learners construct connections between previous and new learning along with developing vocabulary for better thinking and communication. (Contains 3 figures and 4 tables.)
- Published
- 2008
- Full Text
- View/download PDF
13. Exceptionally Potent Anti-Tumor Bystander Activity of an scFv:sTRAIL Fusion Protein with Specificity for EGP2 Toward Target Antigen-Negative Tumor Cells
- Author
-
Edwin Bremer, Douwe Samplonius, Bart-Jan Kroesen, Linda van Genne, Lou de Leij, and Wijnand Helfrich
- Subjects
scFv:sTRAIL ,fusion protein ,bystander ,apoptosis ,EGP2 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Previously, we reported on the target cell-restricted fratricide apoptotic activity of scFvC54:sTRAIL, a fusion protein comprising human-soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) genetically linked to the antibody fragment scFvC54 specific for the cell surface target antigen EGP2. In the present study, we report that the selective binding of scFvC54:sTRAIL to EGP2-positive target cells conveys an exceptionally potent pro-apoptotic effect toward neighboring tumor cells that are devoid of EGP2 expression (bystander cells). The anti-tumor bystander activity of scFvC54:sTRAIL was detectable at target-tobystander cell ratios as low as 1:100. Treatment in the presence of EGP2-blocking or TRAIL-neutralizing antibody strongly inhibited apoptosis in both target and bystander tumor cells. In the absence of target cells, bystander cell apoptosis induction was abrogated. The bystander apoptosis activity of scFvC54:sTRAIL did not require internalization, enzymatic conversion, diffusion, or communication (gap junctional intracellular communication) between target and bystander cells. Furthermore, scFvC54:sTRAIL showed no detectable signs of innocent bystander activity toward freshly isolated blood cells. Further development of this new principle is warranted for approaches where cancer cells can escape from antibody-based therapy due to partial loss of target antigen expression.
- Published
- 2004
- Full Text
- View/download PDF
14. Cardiac function and architecture are maintained in a model of cardiorestricted overexpression of the prorenin-renin receptor.
- Author
-
Hasan Mahmud, Wellington Mardoqueu Candido, Linda van Genne, Inge Vreeswijk-Baudoin, Hongjuan Yu, Bart van de Sluis, Jan van Deursen, Wiek H van Gilst, Herman H W Silljé, and Rudolf A de Boer
- Subjects
Medicine ,Science - Abstract
The (pro)renin-renin receptor, (P)RR has been claimed to be a novel element of the renin-angiotensin system (RAS). The function of (P)RR has been widely studied in renal and vascular pathology but the cardio-specific function of (P)RR has not been studied in detail. We therefore generated a transgenic mouse (Tg) with cardio-restricted (P)RR overexpression driven by the alpha-MHC promotor. The mRNA expression of (P)RR was ∼ 170-fold higher (P
- Published
- 2014
- Full Text
- View/download PDF
15. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.
- Author
-
Maria A Said, Hope L Johnson, Bareng A S Nonyane, Maria Deloria-Knoll, Katherine L O'Brien, AGEDD Adult Pneumococcal Burden Study Team, Felipe Andreo, Bojana Beovic, Silvia Blanco, Wim G Boersma, David R Boulware, Jay C Butler, Jordi Carratalà, Feng-Yee Chang, Patrick G P Charles, Alejandro A Diaz, Jose Domínguez, Naomi Ehara, Henrik Endeman, Vicenç Falcó, Miquel Falguera, Kiyoyasu Fukushima, Carolina Garcia-Vidal, Daniel Genne, Igor A Guchev, Felix Gutierrez, Susanne S Hernes, Andy I M Hoepelman, Ulla Hohenthal, Niclas Johansson, Vitezslav Kolek, Roman S Kozlov, Tsai-Ling Lauderdale, Ivana Mareković, Mar Masiá, Matta A Matta, Òscar Miró, David R Murdoch, Eric Nuermberger, Richard Paolini, Rafael Perelló, Dominic Snijders, Vanda Plečko, Roger Sordé, Kristoffer Strålin, Menno M van der Eerden, Angel Vila-Corcoles, and James P Watt
- Subjects
Medicine ,Science - Abstract
Pneumococcal pneumonia causes significant morbidity and mortality among adults. Given limitations of diagnostic tests for non-bacteremic pneumococcal pneumonia, most studies report the incidence of bacteremic or invasive pneumococcal disease (IPD), and thus, grossly underestimate the pneumococcal pneumonia burden. We aimed to develop a conceptual and quantitative strategy to estimate the non-bacteremic disease burden among adults with community-acquired pneumonia (CAP) using systematic study methods and the availability of a urine antigen assay.We performed a systematic literature review of studies providing information on the relative yield of various diagnostic assays (BinaxNOW® S. pneumoniae urine antigen test (UAT) with blood and/or sputum culture) in diagnosing pneumococcal pneumonia. We estimated the proportion of pneumococcal pneumonia that is bacteremic, the proportion of CAP attributable to pneumococcus, and the additional contribution of the Binax UAT beyond conventional diagnostic techniques, using random effects meta-analytic methods and bootstrapping. We included 35 studies in the analysis, predominantly from developed countries. The estimated proportion of pneumococcal pneumonia that is bacteremic was 24.8% (95% CI: 21.3%, 28.9%). The estimated proportion of CAP attributable to pneumococcus was 27.3% (95% CI: 23.9%, 31.1%). The Binax UAT diagnosed an additional 11.4% (95% CI: 9.6, 13.6%) of CAP beyond conventional techniques. We were limited by the fact that not all patients underwent all diagnostic tests and by the sensitivity and specificity of the diagnostic tests themselves. We address these resulting biases and provide a range of plausible values in order to estimate the burden of pneumococcal pneumonia among adults.Estimating the adult burden of pneumococcal disease from bacteremic pneumococcal pneumonia data alone significantly underestimates the true burden of disease in adults. For every case of bacteremic pneumococcal pneumonia, we estimate that there are at least 3 additional cases of non-bacteremic pneumococcal pneumonia.
- Published
- 2013
- Full Text
- View/download PDF
16. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein
- Author
-
Tychopoulos, Marina, Corcos, Laurent, Genne, Philippe, Beaune, Philippe, and de Waziers, Isabelle
- Published
- 2005
- Full Text
- View/download PDF
17. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts
- Author
-
Gourdeau, Henriette, Genne, Philippe, Kadhim, Salam, Bibeau, Lucie, Duchamp, Olivier, Ouellet, France, deMuys, Jean-Marc, Bouffard, David Y., and Attardo, Giorgio
- Published
- 2002
- Full Text
- View/download PDF
18. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes
- Author
-
Solary, E, Mannone, L, Moreau, D, Caillot, D, Casasnovas, R-O, Guy, H, Grandjean, M, Wolf, J-E, André, F, Fenaux, P, Canal, P, Chauffert, B, Wotawa, A, Bayssas, M, and Genne, P
- Published
- 2000
- Full Text
- View/download PDF
19. Multicentric evaluation of the MDR phenotype in leukemia
- Author
-
Marie, J-P, Huet, S, Faussat, A-M, Perrot, J-Y, Chevillard, S, Barbu, V, Bayle, C, Boutonnat, J, Calvo, F, Campos-Guyotat, L, Colosetti, P, Cazin, J-L, de Cremoux, P, Delvincourt, C, Demur, C, Drenou, B, Fenneteau, O, Feuillard, J, Garnier-Suillerot, A, Genne, P, Gorisse, M-C, Gosselin, P, Jouault, H, Lacave, R, Le Calvez, G, Léglise, M-C, Léonce, S, Manfait, M, Maynadié, M, Merle-Béral, H, Merlin, J-L, Mousseau, M, Morjani, H, Picard, F, Pinguet, F, Poncelet, P, Racadot, E, Raphael, M, Richard, B, Rossi, J-F, Schlegel, N, Vielh, P, Zhou, D-C, and Robert, J
- Published
- 1997
- Full Text
- View/download PDF
20. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours
- Author
-
Chevillard, S, Vielh, Ph, Validire, P, Marie, JP, Faussat, AM, Barbu, V, Bayle, C, Bénard, J, Bonnal, C, Boutonnat, J, Calvo, F, Charrier, J, Clary, A, Colosetti, P, Danel-Moore, L, Decrémoux, P, Delvincourt, C, Finat-Duclos, F, Genne, Ph, Kataki, A, Kouyoumdjian, JC, Lacave, R, Maugard, C, Merlin, JL, Mousseau, M, Pinguet, F, Quillien, V, Raphael, M, Richard, B, Verrelle, P, and Robert, J
- Published
- 1997
- Full Text
- View/download PDF
21. Histological reactivity of a monoclonal antibody against rat colon cancer cells on human and rat normal gut and colonic tumours
- Author
-
Genne, P., Olsson, N. -O., Caignard, A., Oriol, R., Bara, J., Hammann, A., and Martin, F.
- Published
- 1992
- Full Text
- View/download PDF
22. Threshold of the sensitivity to a epileptiform stimulus for intracerebral allotransplantation of embryonal nervous tissue of various ergicity
- Author
-
Ereniev, S. I., Semchenko, V. V., Genne, R. I., and Makovetskii, K. K.
- Published
- 1993
- Full Text
- View/download PDF
23. Multicentric evaluation of the MDR phenotype in leukemia
- Author
-
J-P Marie, S Huet, A-M Faussat, J-Y Perrot, S Chevillard, V Barbu, C Bayle, J Boutonnat, F Calvo, L Campos-Guyotat, P Colosetti, J-L Cazin, P de Cremoux, C Delvincourt, C Demur, B Drenou, O Fenneteau, J Feuillard, A Garnier-Suillerot, P Genne, M-C Gorisse, P Gosselin, H Jouault, R Lacave, G Le Calvez, M-C Léglise, S Léonce, M Manfait, M Maynadié, H Merle-Béral, J-L Merlin, M Mousseau, H Morjani, F Picard, F Pinguet, P Poncelet, E Racadot, M Raphael, B Richard, J-F Rossi, N Schlegel, P Vielh, D-C Zhou, and J Robert
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,biology ,medicine.diagnostic_test ,medicine.drug_class ,Immunocytochemistry ,Fluorescence spectrometry ,Hematology ,Drug resistance ,medicine.disease ,Monoclonal antibody ,Flow cytometry ,Multiple drug resistance ,Leukemia ,Internal medicine ,Immunology ,biology.protein ,medicine ,Antibody - Abstract
The wide discrepancies in the frequency of ‘positive’ samples for multidrug resistance (MDR) phenotype within the same type of tumor observed in the literature justified the need for the definition of consensus recommendations. To define standard techniques of MDR phenotype measurement, we ran a large multicentric evaluation of the different methods available. Thirty-six French centers participated in the study, and 742 samples of 2–10 × 106 viable cells were sent by overnight express mail between December 1993 and February 1996. The same batches of MRK16, 4E3 and UIC2 were used. Nineteen samples of leukemia (12 AML, 1 ALL, 6 lymphoproliferative syndromes) and six leukemic cell lines with different levels of MDR expression were tested. Five meetings reached agreement concerning the guidelines for each technique, except immunocytochemistry. The 19 fresh samples were tested by each center using one to four techniques among cytofluorometry, immunocytochemistry, functional tests and RT-PCR. Five samples were diagnosed as ‘negative’ according to local criteria, with few discordant results (0 to 16% of ‘positive’ results). For all the 14 remaining samples, large discrepancies were observed from center to center, and from one technique to another. No correlations could be found between techniques. Flow cytometric analysis of cells already exposed to MRK16 or control IgG2A, fixed in paraformaldehyde and sent to centers did not reduce the discrepancies between centers in two of the four samples with moderate expression, emphasizing the role of histogram interpretation. The use of alternative monoclonal antibodies (4E3 and UIC2) did not reduce the discrepancies observed. In a second step, the K562 parental cell line, a low resistant subline (K562/HHT100, ×7 resistance index to DNR) and a high resistant subline (K562/HHT300, ×125 resistance index to DNR) were sent blindly three times, with an increasing level of recommendations for flow cytometry. Dramatic improvements were observed in cytometric results when the result was expressed as the ratio of arithmetic mean of fluorescence of antibody (10 μg of MRK16)/arithmetic mean of fluorescence of control (10 μ g IgG2A): the proportion of expected results increased from 61 to 100% for K562, and from 37 to 85% for K562/HHT100. For uptake and drug efflux measurements, the use of 1 h uptake of 0.1μ M of rhodamine, followed by 1 h efflux ±10 μ M of verapamil, permitted an increased reproducibility of the technique from 71 to 100% for K562 and K562/HHT100. Whatever the technique used, concordant results were obtained for K562/HHT300. The immunocytochemistry, using several antibodies (MRK16, JSB1 and C219) gave many non-interpretable results (44%), due to a frequent high background and discordant results between antibodies in the same centers, and discordant conclusions between centers. The group does not recommend this technique for circulating tumoral cells.
- Published
- 1997
24. Effect of ageing on insulin and insulin-glucose sensitivity tests in rats
- Author
-
Gommers, Adrienne and Genne, Henriette
- Published
- 1975
- Full Text
- View/download PDF
25. [Preclinical evaluation of aromatase inhibitors antitumor activity]
- Author
-
P, Auvray, F, Bichat, and P, Genne
- Subjects
Antineoplastic Agents, Hormonal ,Fadrozole ,Aromatase Inhibitors ,Androstenedione ,Drug Evaluation, Preclinical ,Anastrozole ,Triazoles ,Aminoglutethimide ,Rats ,Androstadienes ,Structure-Activity Relationship ,Aromatase ,Letrozole ,Models, Animal ,Nitriles ,Animals ,Humans ,Female ,Enzyme Inhibitors - Abstract
Aromatase is an enzymatic complex responsible for the conversion of androgens into estrogens; these hormones are important in development, reproduction, but also in the growth of estrogen-dependent cancer. This enzyme is present in 60-70% of the breast cancer. The aromatase inhibitors are important drugs in the breast cancer treatment of postmenopausal women. In order to study their in vivo activity, animal models have been developed, e.g. rat with tumour induced by 7,12-dimethylbenz[a]anthracene, PMSG-primed immature rat or athymic nude mice with aromatase transfected MCF-7 xenograft. In this review, we were interested in preclinical results obtained with both classes: steroidal and nonsteroidal inhibitors. The former group, as substrate analogs formestane or exemestane, are irreversible, selective and long-lasting inhibitors of aromatase. The nonsteroidal molecules, such as letrozole or anastrozole, are reversible inhibitors with high affinity. Finally, knowledge of the enzyme active site, with molecular modeling and site-directed mutagenesis, could be useful to develop new inhibitor families, more specific and potent in vivo.
- Published
- 2001
26. French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris
- Author
-
S, Chevillard, P, Vielh, P, Validire, J P, Marie, A M, Faussat, V, Barbu, C, Bayle, J, Bénard, C, Bonnal, J, Boutonnat, F, Calvo, J, Charrier, A, Clary, P, Colosetti, L, Danel-Moore, P, Decrémoux, C, Delvincourt, F, Finat-Duclos, P, Genne, A, Kataki, J C, Kouyoumdjian, R, Lacave, C, Maugard, J L, Merlin, and J, Robert
- Subjects
DNA, Complementary ,Leukemia ,Neoplasms ,Humans ,RNA ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Immunohistochemistry ,Polymerase Chain Reaction - Abstract
Since there is no consensus on the techniques for multidrug resistance (MDR) phenotype evaluation, many discrepancies concerning the importance and frequency of mdr1 gene expression in leukemias and solid tumors are observed in the literature. In order to establish an inter-laboratory consensus in France, a multicenter study was carried out to propose further guidelines for MDR phenotype evaluation. The techniques used by the 38 laboratories participating in the trial were: immunodetection (immunohisto and/or cytochemistry, flow cytometry), functional tests, reverse transcription-polymerase chain reaction (RT-PCR) or Northern blot. We present the results obtained by 19 laboratories concerning the measurement of mdr1 gene expression assessed by RT-PCR or Northern blot in: (1)19 samples of tumor cells obtained from leukemic patients; (2) six solid tumor samples obtained at surgery; (3) eight cell lines exhibiting variable levels of resistance, and; (4)10 preparations of RNA and of cDNA obtained from solid tumors. Standardization of the RT-PCR technique and preliminary results comparing RT-PCR with immunohistochemistry in solid tumors are also reported.
- Published
- 1997
27. Mitoxantrone/Cytarabine with or without Quinine as a Potential MDR- Reversing Agent for the Treatment of Acute Leukemias
- Author
-
Jean-Yves Cahn, P. Lamy, A Sadoun, J-L Harousseau, P. Genne, Bruno Audhuy, Denis Guyotat, Bernard Desablens, Philippe Colombat, Bernard Pignon, Norbert Ifrah, Philippe Casassus, F. Witz, Denis Caillot, Philippe Moreau, Eric Solary, Frédéric Maloisel, and JF Abgrall
- Subjects
Quinine ,Mitoxantrone ,Acute leukemia ,medicine.medical_specialty ,Chemotherapy ,Nausea ,business.industry ,medicine.medical_treatment ,Neutropenia ,medicine.disease ,Gastroenterology ,Internal medicine ,medicine ,Cytarabine ,Mucositis ,medicine.symptom ,business ,medicine.drug - Abstract
We demonstrated previously that sera from quinine-treated patients reversed the MDR phenotype in vitro. Then, the combination of quinine with mitoxantrone (MTX) and cytarabine (Ara-C) was shown to be well-tolerated in patients with acute leukemias. To answer the question whether the response rate could be improved by quinine, we designed a phase III multicentric study. During the first year, the trial involved 112 adult patients (age 18–65y) with either relapsed or refractory acute myeloblastic or lymphoblastic leukemia or secondary leukemia or blastic transformation of myelodysplastic or myeloproliferative syndrome. All patients were treated with a combination of MTX (12 mg/m2/day — 4 days) and Ara-C (1 g/m2/12h — 5 days — 3 hrs iv infusion). After randomisation, 55 patients also received quinine (30 mg/kg/d — 5 days — beginning 24 hrs before MTX infusion). A 20% dose decrease was necessary in 14 patients due to vertigo or tinnitus and quinine was discontinued in 1 patient, due to excessive QT extension The remaining 57 patients received the chemotherapy alone. Toxic death was observed in 2 patients (one in each group) and ten patients (7 in quinine-treated group) died in aplasia before day 30. Response was assessable in 106 patients. As compared with the patients treated with MTX-Ara-C only, the patients treated with MTX-Ara-C plus quinine had a higher overall rate of response [29 / 52 (56%) versus 26 / 54 (48%)]. However, this difference is not significant. Quinine increased the duration of neutropenia (28,3 vs 23,9 days; p < 0.05) and thrombopenia (35 vs 28,3; p = 0.02). The incidence of nausea, vomiting and mucositis was also significantly higher in the quinine-treated group. This partial analysis confirmed the feasibility of using quinine in combination with MTX and Ara-C and suggested a trends for quinine to improve the response rate although these results have to be confirmed by the extended study.
- Published
- 1996
28. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance
- Author
-
P, Genne, O, Duchamp, E, Solary, J, Magnette, J P, Belon, and B, Chauffert
- Subjects
Cinchona Alkaloids ,Quinones ,Administration, Oral ,Biological Availability ,Drug Synergism ,Dexamethasone ,Drug Resistance, Multiple ,Rats ,Doxorubicin ,Vincristine ,Antineoplastic Combined Chemotherapy Protocols ,Colonic Neoplasms ,Tumor Cells, Cultured ,Animals ,Female ,Tissue Distribution ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Infusions, Intravenous - Abstract
We have previously suggested that quinine and cinchonine could be good candidates for the clinical circumvention of multidrug resistance (MDR) in haematological malignancies because of their tolerance and their retained efficacy in serum. We have also shown that cinchonine was more efficient than quinine as an anti-MDR agent in vitro, ex vivo and in vivo after parenteral administration. Here, we report that cinchonine administered per os (po) is much more active than quinine po in circumventing MDR in rats bearing resistant colon tumours. The pharmacokinetics of cinchonine and quinine administered po in rat are shown to be very different. Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively). Its serum concentration correlates with the anti-MDR activity measured ex vivo and in vivo. Cinchonine administered po does not significantly modify the pharmacokinetics of intravenous doxorubicin (DXR). However, cinchonine induces a significant increase of DXR uptake in organs which express the mdr1 gene (liver, kidney, lung). When associated with VAD (vincristine, adriamycin, dexamethasone) combined therapy in rats, cinchonine does not significantly increase the toxicity of the cytotoxic drugs. Based on these experimental data, a phase I clinical trial is currently in progress to test the tolerance of this potent MDR-reversing agent administered po.
- Published
- 1995
29. Der Weg zur Lean Quality 4.0
- Author
-
Enke, Judith, Meister, Maximilian, Metternich, Joachim, Genne, Michael, and Brosche, Justus
- Abstract
Mit Industrie 4.0 als Zukunftsvision des deutschen Produktionsstandorts stellt sich die Frage, wie bewährte Verbesserungsansätze mit den neuen, digitalen Möglichkeiten vereint bzw. weiterentwickelt werden können. Insbesondere sind Qualitätstechniken hinsichtlich der kontinuierlichen Verbesserung von Produkten und Prozessen von großer Bedeutung für ganzheitliche Produktionssysteme. Es entsteht somit die Notwendigkeit, die Kombination beider Ansätze im Rahmen einer integrierten Lean Quality 4.0 zu untersuchen. Dazu werden ein systematisches Vorgehen entlang eines kreativen Problemlösungsprozesses sowie ermittelte Szenarien vorgestellt.
- Published
- 2017
- Full Text
- View/download PDF
30. [Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia]
- Author
-
E, Solary, F, Witz, P, Moreau, I, Quiquandon, P, Genne, M, Flesch, A, Saddoun, F, Maloisel, B, Pignon, and J F, Abgrall
- Subjects
Male ,Leukemia ,Quinine ,Recurrence ,Acute Disease ,Antineoplastic Combined Chemotherapy Protocols ,Cytarabine ,Humans ,Female ,Middle Aged ,Mitoxantrone - Published
- 1994
31. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice
- Author
-
P, Genne, N O, Olsson, G, Gutierrez, O, Duchamp, and B, Chauffert
- Subjects
Male ,Drug Carriers ,Mice, Inbred BALB C ,Carcinoma ,Mice ,Colonic Neoplasms ,Liposomes ,Electrochemistry ,Tumor Cells, Cultured ,Animals ,Female ,Tissue Distribution ,Mitoxantrone ,Neoplasm Transplantation ,Peritoneal Neoplasms - Abstract
Since liposomes are slowly resorbed from serous cavities, they may constitute a valuable tool for the treatment of peritoneal carcinomatosis. We prepared mitoxantrone (MXN)-liposomes with various lipid compositions and checked their antitumoral activity on a peritoneal carcinomatosis induced by a colon cancer cell injection (1 x 10(5) C51 cells) in BALB/c mice. MXN entrapment in liposomes was rapid and stable due to its high lipophilicity. MXN carried in phosphatidylcholine: cholesterol (2:1; G-liposomes) displayed a reduced toxicity in mice compared to the free drug. When tested at a non-toxic dose (2 mg/kg), MXN entrapped in G-liposomes proved to be as efficient as the free drug. At a higher MXN dose (3 mg/kg), both G-liposomes and phosphatidylcholine:cholesterol:dipalmitoylphosphatidylethanolamine (7:2:1) liposomes, loaded with MXN, significantly increased the life span of mice compared to the free drug and six other liposome formulations. Increase in the MXN therapeutic index, when used in the liposomal form, could then merit further clinical investigations in regard to patients with malignancies confined to serous cavities.
- Published
- 1994
32. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion
- Author
-
H, Pelletier, J M, Millot, B, Chauffert, M, Manfait, P, Genne, and F, Martin
- Subjects
Cell Nucleus ,Diffusion ,Antibiotics, Antineoplastic ,Doxorubicin ,Colonic Neoplasms ,Drug Resistance ,Tumor Cells, Cultured ,Animals ,Humans ,Rats - Abstract
Two colon cancer cell lines, HT-29 (human) and DHD/K12/TRb (rat), were grown as monolayer cultures to various confluence degrees. The cytotoxic efficacies of doxorubicin and 4'-deoxydoxorubicin, evaluated by a survival assay, and the nuclear drug concentrations, measured by microspectrofluorometry, were shown to progressively decrease with the augmentation of confluence. This confluence dependent resistance (CDR) to anthracyclines was demonstrated independent of the multidrug resistance drug efflux mechanism. The cellular uptake of three compounds (sodium [51Cr]chromate, D-[14C]alanine, L-[14C]glucose) known to passively diffuse across the cell membrane as anthracyclines do was also reduced in confluent cells. After trypsin cell detachment, the kinetics of reversion of the sodium [51Cr]chromate uptake decrease and that of CDR were similar. Therefore, CDR may be attributed to a reduction of anthracycline cell intake due to a general alteration of passive diffusion across the cell membrane. However, CDR is only partly explained by this phenomenon since a reduced sensitivity of confluent cells was observed compared with nonconfluent cells for a similar amount of drug in their nuclei. CDR could explain the high resistance to anthracyclines of some solid tumors, such as colon tumors, in which cancer cells are tightly aggregated.
- Published
- 1990
33. A Theory of the Drone, Grégoire Chamayou (2015), New York: New Press
- Author
-
Speers, Genne
- Abstract
Abstract
- Published
- 2016
- Full Text
- View/download PDF
34. Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system.
- Author
-
Kuipers, Irma, van der Harst, Pim, Navis, Gerjan, van Genne, Linda, Morello, Fulvio, H. van Gilst, Wiek, van Veldhuisen, Dirk J., de Boer, Rudolf A., and van Gilst, Wiek H
- Abstract
The article discusses the relationship which nuclear hormone receptors (NHR) have with the renin-angiotensin-aldosterone system (RAAS). Research which has been completed which found a close relationship between the RAAS and NHR is discussed. The role that NHRs play in the RAAS and the human body as a whole is mentioned.
- Published
- 2008
- Full Text
- View/download PDF
35. Preclinical study of cinchonine, a powerful MDR reversing agent
- Author
-
D. Caillot, Eric Solary, P. Genne, Bruno Chauffert, Laurence Dubrez, Duchamp O, R O Casasnovas, and H. Guy
- Subjects
Pharmacology ,Cancer Research ,chemistry.chemical_compound ,Oncology ,Chemistry ,Pharmacology (medical) ,Reversing ,Cinchonine - Published
- 1994
36. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
- Author
-
Ananworanich, J., Gayet-Ageron, A., Le Braz, M., Prasithsirikul, W., Chetchotisakd, P., Kiertiburanakul, S., Munsakul, W., Raksakulkarn, P., Tansuphasawasdikul, S., Sirivichayakul, S., Cavassini, M., Karrer, U., Genne, D., Nuesch, R., Vernazza, P., Bernasconi, E., Leduc, D., Satchell, C., Yerly, S., Perrin, L., Hill, A., Perneger, T., Phanuphak, P., Furrer, H., Cooper, D., Ruxrungtham, K., and Hirschel, B.
- Abstract
Background: Stopping antiretroviral therapy in patients with HIV-1 infection can reduce costs and side-effects, but carries the risk of increased immune suppression and emergence of resistance. Methods: 430 patients with CD4-positive T-lymphocyte (CD4) counts greater than 350 cells per @mL, and viral load less than 50 copies per mL were randomised to continued therapy (n=146) or scheduled treatment interruptions (n=284). Median time on randomised treatment was 21.9 months (range 16.4-25.3). Primary endpoints were proportion of patients with viral load less than 50 copies per mL at the end of the trial, and amount of drugs used. Analysis was intention-to-treat. This study is registered at ClinicalTrials.gov with the identifier NCT00113126. Findings: Drug savings in the scheduled treatment interruption group, compared with continuous treatment, amounted to 61.5%. 257 of 284 (90.5%) patients in the scheduled treatment interruption group reached a viral load less than 50 copies per mL, compared with 134 of 146 (91.8%) in the continued treatment group (difference 1.3%, 95% CI-4.3 to 6.9, p=0.90). No AIDS-defining events occurred. Diarrhoea and neuropathy were more frequent with continuous treatment; candidiasis was more frequent with scheduled treatment interruption. Ten patients (2.3%) had resistance mutations, with no significant differences between groups. Interpretation: Drug savings with scheduled treatment interruption were substantial, and no evidence of increased treatment resistance emerged. Treatment-related adverse events were more frequent with continuous treatment, but low CD4 counts and minor manifestations of HIV infection were more frequent with scheduled treatment interruption.
- Published
- 2006
- Full Text
- View/download PDF
37. Polysulfone-aerosil composite membranes
- Author
-
Aerts, P., Genne, I., Kuypers, S., Leysen, R., Vankelecom, I. F., and Jacobs, P. A.
- Published
- 2000
- Full Text
- View/download PDF
38. Effect of the addition of ZrO~2 to polysulfone based UF membranes
- Author
-
Genne, I., Kuypers, S., and Leysen, R.
- Published
- 1996
- Full Text
- View/download PDF
39. Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells
- Author
-
Assem, M, Bonvalot, S, Beltramo, JL, Garrido, C, Dimanche-Boitrel, MT, Genne, P, Rebibou, JM, Caillot, D, and Chauffert, B
- Abstract
Inherent resistance of colon cancer cells to cis-diamminedichloroplatinum(II) (CDDP) is partly attributed to reduced drug penetration through plasma membrane. Amphotericin B (AmB), a polyene antifungal antibiotic, has been shown to increase CDDP penetration and cytotoxicity on several non-digestive cancer cell lines. We demonstrated here that AmB dramatically increases the penetration of CDDP, and to a lesser extent that of carboplatin (Carbo-P) and oxaloplatin (L-OHP), in the primary resistant HT 29 human colon cancer cells when drug incubation is performed in serum-free medium. The cytotoxicity of CDDP but not that of Carbo-P and L-OHP was increased by AmB. However, AmB-induced potentiation of CDDP penetration and toxicity was almost completely abolished when cell incubation was performed in presence of human serum. We investigated whether the dilution of human serum by a high osmotic power gelatine solution (Lomol) could restore the positive effect of AmB on CDDP accumulation in HT 29 cells. Incubation of cells with CDDP and AmB in pure Lomol resulted in a 6-fold increase in platinum cellular content. However, addition of serum (25%) in Lomol solution reduced to only 2-fold the increase in platinum cellular content provoked by AmB. These disappointing results show that AmB is probably uninteresting as a modulator of CDDP resistance in clinical practice. The use of haemodilution to restore the positive AmB effect on platinum cellular accumulation cannot be warranted.
- Published
- 1994
- Full Text
- View/download PDF
40. Large-plant sulfur recovery processes stress efficiency.
- Author
-
Goar, B. Genne and Nasato, Elmo
- Subjects
NATURAL gas ,DESULFURIZATION - Abstract
Reviews several gas treating and sulfur-recovery processes in use by natural gas companies. Considerations involved in building a sour-gas treating and sulfur-recovery plants; Sample plants employing major technologies; Selection of the best gas-treating process.
- Published
- 1994
41. Pasteurella multocida Endocarditis: Report of a Case and Review of the Literature
- Author
-
Genne, Daniel, Siegrist, Hans, Monnier, Patrick, Nobel, Monica, Humair, Luc, and de Torrente, Antoine
- Abstract
We report on a cirrhotic patient who presented with an aortic valve endocarditis due to Pasteurella multocida. This disease entity is rare and we take this opportunity to review the 6 cases published to date.
- Published
- 1996
- Full Text
- View/download PDF
42. Organo-Mineral Ultrafiltration Membranes
- Author
-
Genne, I., Doyen, W., Adriansens, W., and Leysen, R.
- Published
- 1997
- Full Text
- View/download PDF
43. 139 POSTER Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate.
- Author
-
Bichat, F., Demeule, M., Lawrence, B., Raguin, O., Sourzat, B., Gabathuler, R., P. Castaigne, J., and Genne, P.
- Published
- 2008
- Full Text
- View/download PDF
44. Temozolomide and radiotherapy antitumor efficacy evaluation with magnetic resonance imaging and proton magnetic resonance spectroscopy in human glioma models in nude rats.
- Author
-
Tizon, X., Walker, P., Bichat, F., Parfait, S., Miteran, J., Crehange, G., Maingon, P., Hoffman, N., Genne, P., and Duchamp, O.
- Published
- 2008
- Full Text
- View/download PDF
45. Magnetic resonance imaging study of carmustin and sorafenib antitumor efficacy evaluation in orthotopic human glioblastoma models xenografted in nude rats.
- Author
-
Duchamp, O., Lemasson, B., Christen, T., Tizon, X., Farion, R., Barbier, E., Cegebarth, C., Genne, P., and Rémy, C.
- Published
- 2008
- Full Text
- View/download PDF
46. Evaluation of tumor response to carmustin and sorafenib with magnetic resonance imaging in orthotopic human glioblastoma models xenografted in nude rats.
- Author
-
Lemasson, B., Christen, T., Tizon, X., Farion, R., Barbier, E., Segebarth, C., Genne, P., Rémy, C., and Duchamp, O.
- Published
- 2008
- Full Text
- View/download PDF
47. Confluence dependent resistance (CDR) to doxorubicin and E-cadherin expression in murine mammary cells
- Author
-
Dimanche-Boitrel, M. T., Genne, P., Duchamp, O., and Chauffert, B.
- Published
- 1994
- Full Text
- View/download PDF
48. Biochemical characterization and NMR studies of the nucleotide-binding domain 1 of multidrug-resistance-associated protein 1: evidence for interaction between ATP and Trp653
- Author
-
Odile Ramaen, Sandrine Masscheleyn, Marine Oberkampf, Olivier Pamlard, Francis Duffieux, Véronique Stoven, Eric Jacquet, Jean-Yves Lallemand, Institut de Chimie des Substances Naturelles (ICSN), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Résonance Magnétique Nucléaire des Biomolécules, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), We thank the association ‘Vaincre la mucoviscidose’ for financial support and a postdoctoral grant to F. D., the association ABCF-Protein for a grant to M. O. and the Region Ile-de-France for financial support for the Varian 600 MHz spectrometer of Institut Pasteur, We thank Dr P. Genne (Oncodesign) for the gift of HL60/ADR cells, Emeric Miclet and Jérome Bignon for scientific discussions and Muriel Lainé for a critical reading of the manuscript., Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), and Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]
- Subjects
MESH: Amino Acid Sequence ,medicine.disease_cause ,Biochemistry ,MESH: Protein Structure, Tertiary ,0302 clinical medicine ,Adenosine Triphosphate ,MESH: Nuclear Magnetic Resonance, Biomolecular ,Nucleotide ,Magnesium ,MESH: Adenosine Diphosphate / metabolism ,MESH: Multidrug Resistance-Associated Proteins / genetics ,chemistry.chemical_classification ,MESH: Magnesium / physiology ,Adenosine Triphosphatases ,0303 health sciences ,ABC (ATP-binding cassette) ,Tryptophan ,Recombinant Proteins ,Adenosine Diphosphate ,MESH: Adenosine Triphosphatases / metabolism ,Cyclic nucleotide-binding domain ,030220 oncology & carcinogenesis ,MESH: Multidrug Resistance-Associated Proteins / chemistry ,nucleotide-binding domain ,ABCC1 ,Multidrug Resistance-Associated Protein 1 ,medicine.symptom ,Multidrug Resistance-Associated Proteins ,MESH: Spectrometry, Fluorescence ,Research Article ,MESH: Tryptophan / physiology ,Molecular Sequence Data ,MESH: Sequence Alignment ,HL-60 Cells ,Biology ,MESH: Multidrug Resistance-Associated Proteins / metabolism ,03 medical and health sciences ,Residue (chemistry) ,MESH: HL-60 Cells ,MESH: Adenosine Triphosphate / metabolism ,medicine ,Humans ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Amino Acid Sequence ,[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] ,Molecular Biology ,Escherichia coli ,Nuclear Magnetic Resonance, Biomolecular ,030304 developmental biology ,MRP1/ABCC1 (multidrug-resistance-associated protein 1) ,MESH: Tryptophan / metabolism ,MESH: Humans ,MESH: Molecular Sequence Data ,Binding Sites ,MESH: Recombinant Proteins / isolation & purification ,Transporter ,Cell Biology ,Protein Structure, Tertiary ,ATP binding and hydrolysis ,Spectrometry, Fluorescence ,chemistry ,Mechanism of action ,MESH: Binding Sites ,biology.protein ,biochemical and NMR studies ,MESH: Recombinant Proteins / metabolism ,Sequence Alignment - Abstract
International audience; Multidrug-resistance-associated protein 1 (MRP1/ABCC1) is a human ATP-binding cassette transporter that confers cell resistance to antitumour drugs. Its NBDs (nucleotide-binding domains) bind/hydrolyse ATP, a key step in the activation of MRP1 function. To relate its intrinsic functional features to the mechanism of action of the full-size transporter, we expressed the N-terminal NBD1 domain (Asn(642) to Ser(871)) in Escherichia coli. NBD1 was highly purified under native conditions and was characterized as a soluble monomer. (15)N-labelling allowed recording of the first two-dimensional NMR spectra of this domain. The NMR study showed that NBD1 was folded, and that Trp(653) was a key residue in the NBD1-ATP interaction. Thus, interaction of NBD1 with ATP/ADP was studied by intrinsic tryptophan fluorescence. The affinity for ATP and ADP were in the same range (K (d(ATP))=118 microM and K (d(ADP))=139 microM). Binding of nucleotides did not influence the monomeric state of NBD1. The ATPase activity of NBD1 was magnesium-dependent and very low [V (max) and K (m) values of 5x10(-5) pmol of ATP x (pmol NBD1)(-1) x s(-1) and 833 microM ATP respectively]. The present study suggests that NBD1 has a low contribution to the ATPase activity of full-length MRP1 and/or that this activity requires NBD1-NBD2 heterodimer formation.
- Published
- 2003
49. In-vivo metabolic characterization of healthy prostate and orthotopic prostate cancer in rats using proton magnetic resonance spectroscopy at 4.7 T.
- Author
-
Walker P, Provent P, Tizon X, Créhange G, Duchamp O, Brunotte F, and Genne P
- Subjects
- Animals, Cell Line, Tumor, Choline metabolism, Creatine metabolism, Humans, Inositol metabolism, Magnetic Resonance Imaging, Male, Models, Animal, Rats, Rats, Nude, Rats, Sprague-Dawley, Transplantation, Heterologous, Magnetic Resonance Spectroscopy methods, Prostate metabolism, Prostatic Neoplasms metabolism
- Abstract
Background: To assist the development of new anti-cancer drugs, it is important to identify biomarkers of treatment efficacy in the preclinical phases of drug development. In order to improve the predictivity of preclinical experiments, more realistic animal models are needed, for example, tumors xenografted directly on the prostate gland of rodents., Purpose: To characterize the in-vivo metabolism of healthy rat prostate and of an orthotopic human prostate cancer model using proton magnetic resonance spectroscopy (MRS)., Material and Methods: The highly metastatic and hormone-independent PC3-MM2 human prostate cancer model was implanted into the ventral prostate lobe of three Nude rats. Healthy Nude (n = 6) and Sprague-Dawley (n = 6) rats were also studied for interspecies comparison of normal prostate metabolism. Magnetic resonance imaging and short echo-time (TE 11.2 ms) single voxel PRESS spectroscopy were performed on dorsal (DP) and ventral (VP) prostate as well as tumor at 4.7 T. The metabolic content and volume of dorsal and ventral lobes were characterized as a function of species and age., Results: Slightly lower total creatine (tCr)/water (11.3 ± 2.6 vs. 15.3 ± 3.0, NS), but significantly higher Inositol (Ins)/water (18.9 ± 1.9 vs. 6.6 ± 3.3, P < 0.003) and total choline (tCho)/water (15.0 ± 2.1 vs. 5.6 ± 1.1, P < 0.00007) were observed within healthy DP lobes with respect to VP lobes. No significant variation in metabolic content was seen in healthy DP and VP lobes of Nude rats as a function of age, and no species dependence was observed in their metabolic content. For the orthotopic PC3-MM2 tumor, implanted in VP, the tCr/water ratio was significantly lower (3.1 ± 0.9) than neighboring DP (12.8 ± 1.8, P < 0.00003) and healthy VP (15.3 ± 3.0, P < 0.00006). For Ins, the metabolite ratio in PC3-MM2 was close to that of healthy VP (4.3 ± 2.8 vs. 6.6 ± 3.3, p = NS), but much lower than in neighboring DP (19.1 ± 1.3, P < 0.00005). A similar trend was also observed for tCho, where metabolite ratios in PC3-MM2, healthy VP and neighboring DP were 3.5 ± 0.9, 5.6 ± 1.1, and 15.9 ± 0.8, respectively., Conclusion: The in-vivo MRS study of healthy prostate and orthotopic prostate cancer is feasible in rats. Such baseline data could be important when following the modifications in metabolism, including during anti-cancer drug development protocols or following radiotherapy.
- Published
- 2013
- Full Text
- View/download PDF
50. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
- Author
-
Lemasson B, Christen T, Tizon X, Farion R, Fondraz N, Provent P, Segebarth C, Barbier EL, Genne P, Duchamp O, and Remy C
- Subjects
- Angiogenesis Inhibitors pharmacology, Animals, Benzenesulfonates pharmacology, Benzenesulfonates therapeutic use, Blood Volume drug effects, Carmustine pharmacology, Carmustine therapeutic use, Cell Death drug effects, Cell Line, Tumor, Glioma blood supply, Humans, Male, Microvessels drug effects, Microvessels pathology, Models, Biological, Niacinamide analogs & derivatives, Phenylurea Compounds, Pyridines pharmacology, Pyridines therapeutic use, Rats, Rats, Nude, Sorafenib, Staining and Labeling, Survival Analysis, Angiogenesis Inhibitors therapeutic use, Glioma drug therapy, Glioma pathology, Magnetic Resonance Imaging methods
- Abstract
Early imaging or blood biomarkers of tumor response is needed to customize anti-tumor therapy on an individual basis. This study evaluates the sensitivity and relevance of five potential MRI biomarkers. Sixty nude rats were implanted with human glioma cells (U-87 MG) and randomized into three groups: one group received an anti-angiogenic treatment (Sorafenib), a second a cytotoxic drug [1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU (Carmustine)] and a third no treatment. The tumor volume, apparent diffusion coefficient (ADC) of water, blood volume fraction (BVf), microvessel diameter (vessel size index, VSI) and vessel wall integrity (contrast enhancement, CE) were monitored before and during treatment. Sorafenib reduced tumor CE as early as 1 day after treatment onset. By 4 days after treatment onset, tumor BVf was reduced and tumor VSI was increased. By 14 days after treatment onset, ADC was increased and the tumor growth rate was reduced. With BCNU, ADC was increased and the tumor growth rate was reduced 14 days after treatment onset. Thus, the estimated MRI parameters were sensitive to treatment at different times after treatment onset and in a treatment-dependent manner. This study suggests that multiparametric MR monitoring could allow the assessment of new anti-tumor drugs and the optimization of combined therapies., (Copyright © 2010 John Wiley & Sons, Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.